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Abstract 
Peptide α-amidation is known as a signature of bioactivity due to the fact that half of 
the bioactive peptides found in the nervous and endocrine systems are α-amidated and 
that most known α-amidated peptides are bioactive. α-Amidated peptides are produced 
by the oxidative cleavage of glycine-extended precursors. Peptidylglycine α-amidating 
monooxygenase (PAM) is the only known enzyme responsible for catalyzing this 
reaction and its sole physiological function is to convert glycine extended prohormones to 
their α-amidated forms. High levels of PAM are found in certain tissues with no 
corresponding level of amidated products suggesting the presence of undiscovered 
α-amidated peptide hormones.  
Liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) has 
emerged as a powerful tool for peptide identification due to its advantages of speed, 
sensitivity and applicability to complex peptide mixtures. Normally, spectra are 
interpreted using database search engines. However, database searching is inefficient and 
ineffective for the identification of endogenous peptide with post-translational 
modifications (PTM) due to its low identification rate and high demand for computing 
power.  
 x 
 
There is a specific mass difference of 58.0055 units between an α-amidated peptide 
and its corresponding C-terminal glycine-extended precursor. The two peptides will have 
similar chromatographic retention time and MS/MS fragmentation patterns resulting from 
the identical amino acids sequences except for relatively the small differences at the 
C-termini. Based on this, a new LC-MS/MS based strategy for screening for α-amidated 
peptides was developed. This strategy depends on PAM inhibition and the mass accuracy 
of mass spectrometry (< 3 ppm). The coexistence of α-amidated peptides and their 
C-terminal glycine-extended precursors was insured by growing cells in the presence of a 
PAM inhibitor. After LC-MS/MS, masses and retention times of parent ions were 
extracted from raw data files and scanned by a script for peptide pairs with similar 
retention times and a mass difference around 58.0055. Resulting pairs were further 
validated by comparing their fragmentation patterns in MS/MS spectra. Only peptide 
pairs that met all three criteria were considered for further interpretation. This reduced the 
number of MS/MS spectra requiring interpretation by >99% and, thus, enable the manual 
inspection of MS/MS for the candidate peptide pairs. A total of 13 α-amidated peptides 
were successfully identified from cultured mouse pituitary AtT-20 cells using this 
method and a few of these newly identified α-amidated peptides exhibited bioactivity.   
The adaptability of this strategy to screening for other PTMs is also discussed. 
 xi 
 
Peptidylglycine α-hydroxylating monooxygenase (PHM) is one of PAM domains 
which can be expressed separately. It is a copper dependent enzyme that catalyzes the 
first step of the two-step peptide amidation reaction. Removal of the copper ions results 
in the loss of enzyme catalytic activity. A PHM based α-amidated peptide enrichment 
method was developed. This method includes two steps. First, cells grown in culture were 
treated with a PAM inhibitor to effect the cellular accumulation of glycine-extended 
peptides. In the second step, copper-depleted PHM (apo-PHM) was used to selectively 
bind glycine-extended peptides present in the cell extract. All other unbound peptides 
were removed during wash runs. apo-PHM was then reinstated with copper to convert 
bound glycine-extended peptides to hydroxylated peptides and release them. 
Hydroxylated product can be converted to α-amidated peptide under basic conditions. 
Experiments carried out using model glycine extended peptides showed a 40 – 120-fold 
enrichment using HPLC-fluorometric assay or MALDI-TOF quantification. This method 
proved successful when working with complex samples like cell extracts. The relative 
intensity of a known α-amidated peptide mouse joining peptide (mJP) from an AtT-20 
extract was dramatically increased after enrichment experiments.  
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Chapter 1 Introduction 
1.1 Peptide Amidation 
1.1.1 Peptide amidation and its biological significance.  
Post-translational modification (PTM) is a chemical modification of a polypeptide 
chain which results from either the addition or removal of chemical groups to amino acid 
residues, proteolytic processing, or formation of disulfide cross-links. More than 300 
different types of PTMs have been discovered and this number is increasing (Witze et al. 
2007). As a consequence of PTM, different modified forms of a gene product may be 
present in vivo each with a different cellular function. Through changing proteins’ mass, 
charge, structure or hydrophobicity, PTMs can control proteins’ activity and stability, 
protein subcellular localization and protein-protein interaction (Parekh and Rohlff 1997).  
C-terminal amidation is an important PTM. About half of the bioactive peptides 
found in the nervous and endocrine systems are α-amidated (Eipper, Stoffers and Mains 
1992, Eipper and Mains 1988), such as corticotropin-releasing hormone (CRH), 
thyrotropin releasing hormone (TRH), neuropeptide Y (NPY), substance P, oxytocin, 
vasopressin and α-melanotropin. For most of these peptides, the presence of the 
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C-terminal amide structure is essential for their biological activity and stability. Merkler 
defined a numerical value “potency ratio” to study the contribution of C-terminal amide 
in α-amidated peptides as compared to the corresponding peptides with free C-terminal 
acid (Merkler 1994). In this study, the potency ratios of 33 peptides known to be 
amidated in vivo were summarized. Of these, nine peptides showed a potency ratio 
greater or equal 1,000 (Table 1). Most peptides (27 out of 33) exhibited at least 10-fold 
increase in activity with the presence of C-terminal amide. Only 3 of the 33 peptides did 
not show significant activity change. On the other hand, by replacing free carboxylic acid 
group with unionizable amide group at C-terminus, α-amidation may change the 
hydrophobicity of peptide and, thus, increase the affinity of the peptide to the cognate 
receptor. Studies on cholecystokinin-A receptor (CCK-AR), a G protein-coupled receptor, 
showed that the amide moiety was a key determinant in the interaction between the 
receptor and its amidated peptide ligands (Gigoux et al. 1999). This conclusion was 
further supported by another study on the activities of CCK derivatives without α-amide 
(Lignon et al. 1987).
 3 
 
 
Table 1.  Potency ratio of endogenous α-amidated peptides. 
 
Peptide Source 
Amino 
acids 
C-terminus 
Potency 
ratioa 
Neurokinin A Mammalian 10 Met-NH2 >10,000 
Allatostatin Cockroach 13 Leu-NH2 >10,000 
Lem-KI Cockroach 8 Gly-NH2 ~10,000 
Thyrotropin releasing hormone Porcine, ovine 3 Pro-NH2 4,400 
Red pigment concentration hormone Shrimp 8 Trp-NH2 2,500 
Calcitonin Human 32 Pro-NH2 1,670 
Corticotropin-releasing hormone Ovine 41 Ala-NH2 1,000 
Luteinizing hormone-releasing 
hormone 
Porcine 10 Gly-NH2 1,000 
Leucopyrokinin Cockroach 8 Leu-NH2 1,000 
aThe potency ratio is defined as the activity of a peptide amide divided by the activity of 
its corresponding peptide free acid. 
Data adapted from (Merkler 1994). 
 
 
 4 
 
1.1.2 Biosynthesis of α-amidated peptide and peptidylglycine α-amidating 
monooxygenase. 
Endogenous peptides are derived from prohormone precursors by limited proteolysis 
within the secretory pathway. Nine mammalian prohormone convertases (PCs) 
responsible for tissue specific processing of prohormone precursors have been identified. 
Of these, seven (PC1, PC2, furin, PC4, PC5, PACE4 and PC7) belong to the yeast kexin 
subfamily of subtilases. These PCs cleave the prohormone precursors on the C-terminal 
side of two basic amino acid residues separated by 0, 2, 4 or 6 residues (Seidah and 
Chretien 1999). Another characterized PC is subtilisin kexin isozyme (SKI-1/S1P) which 
belongs to the pyrolysin subfamily of subtilases. SKI-1 cleaves on the C-terminal side of 
Leu or Thr while the second residue ahead the cleavage site being hydrophobic and the 
fourth being basic (Seidah and Chretien 1999) (Table 2). The other PC is neural 
apoptosis-regulated convertase 1 (NARC-1/PCSK9) which belongs to the proteinase K 
subfamily of subtilases. This convertase autocatalytically cleaves its prosegment at the 
motif VFAQ↓SIP (Benjannet et al. 2004). 
 5 
 
After the convertase cleavage, one or more residues are usually removed from the 
C-terminus of peptide-processing intermediate by carboxypeptidases. The peptide may 
then undergo PTMs before they become active.  
Table 2.  Processing sites of mammalian prohormone convertases. 
Cleavage Site Prohormone Convertase 
(K/R)-(X)n-(K/R)↓ PC1, PC2, furin, PC4, PC5, PACE4 and PC7 
(K/R)-X-(Hydrophobic)-(L/T)↓ SKI-1/S1P 
VFAQ↓SIP NARC-1/PCSK9 
X is any amino acid residues. ↓ denotes the cleavage site. 
 
1.1.2.1 Peptidylglycine α-amidating monooxygenase. 
A C-terminal glycine is required for amidation in vivo (Eipper and Mains 1988). 
Peptidylglycine α-amidating monooxygenase (PAM; E.C. 1.14.17.3) is the only enzyme 
known to catalyze the oxidation of inactive C-terminal glycine-extended peptides to their 
bioactive α-amidated products. PAM is a bifunctional enzyme with two distinct catalytic 
domains: peptidylglycine α-hydroxylating monooxygenase (PHM) and 
peptidylamidoglycolate lyase (PAL). The PHM domain is located at the N-terminal of the 
PAL domain, separated by a noncatalytic segment exon A. PHM and PAL can also be 
expressed separately or generated by endoproteolytic cleavage of bifunctional PAM 
(Prigge et al. 2000). 
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PAM is a metalloenzyme with two coppers in PHM domain and one zinc atom in 
PAL domain (Eipper et al. 1995, Bell et al. 1997).  The two coppers in PHM are 
redox-active and cycle between Cu+ and Cu2+ during catalysis (Eipper et al. 1995, 
Freeman, Villafranca and Merkler 1993). Reduced PHM, with two Cu+ atoms, catalyzes 
the reduction of molecular oxygen for the hydroxylation of glycine-extended substrates. 
The PHM-bound Cu2+ atoms can be reduced to Cu+ by a variety of reducing agent, with 
ascorbate exhibiting the highest V/K for those reductants tested. (Kolhekar, Mains and 
Eipper 1997, Li, Oldham and May 1994) Ascorbate is, most likely, the reductant in vivo 
(Eipper and Mains 1991). The role of the PAL-bound Zn(II) remains unclear, as it may 
serve either a structural or catalytic role (Bell et al. 1997, Takahashi et al. 2009). 
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Figure 1.  Representation of PHM Structure (Prigge et al. 1997). 
The active site of PHM is flanked by two coppers represented by brown spheres. 
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Both copper and zinc atoms bound to PAM can be removed using chelators resulting in 
the loss of enzymatic activity. Addition of metals restores catalytic activity (Bell et al. 
1997). 
 
Figure 2.  Representation of PAL structure (Chufan et al. 2009). 
The zinc atom is represented by a gray sphere. 
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1.1.2.2 α-Amidation reaction catalyzed by PAM. 
The two catalytic domains of PAM work sequentially to catalyze the conversion of  
glycine-extended peptides to α-amidated peptides (Figure 3). The oxygen, copper, and 
ascorbate dependent PHM domain removes the pro-S hydrogen for the hydroxylation of 
the α-carbon of C-terminal glycine. The zinc dependent PAL domain dealkylates the 
hydroxyglycine intermediate to the α-amidated product and glyoxylate.  
 
Peptide N
H
OH
O
O
O2
H2o
Peptide N
H
OH
O
O
OH
Peptide NH2
O
O
O
O2 Ascorbate 2 Semidehydroascorbate
PAM
+
PALPHM
 
Figure 3.  Peptide amidation reaction scheme. 
Bifunctional enzyme PAM consists of two catalytic domains: peptidylglycine 
α-hydroxylating monooxygenase (PHM) and peptidylamidoglycolate lyase (PAL). PHM 
domain catalyzes the hydroxylation at the α-carbon of C-terminal glycine. PAL domain 
converts the peptidyl-α-hydroxyglycine to α-amidated peptide and glyoxylate. 
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 1.1.2.3 The rate limiting role of PAM in α-amidated peptide biosynthesis. 
PAM catalyzes the final step in the biosynthesis of α-amidated peptide hormones.  
For most α-amidated peptide hormones, the amidation is essential to the bioactivity 
expressed by the peptide (Table 1). The PAM reaction is also the rate limiting step for the 
in vivo production of the α-amidated peptides. Evidence to support this includes the 
identification of glycine-extended precursors in tissue extracts. In some cases, the 
glycine-extended precursors were found in higher concentrations than the mature 
amidated forms. Examples include the concentration of glycine-extended precursor for 
thyrotropin releasing hormone (TRH-Gly) being 100-fold higher than the α-amidated 
form in the rat ventral prostate (Pekary, Knoble and Garcia 1989), and the concentration 
of glycine-extended form of adrenomedullin being >5-fold higher than that of α-amidated 
adrenomedullin in healthy human plasma (Kitamura et al. 1998). 
Mains et al. (Mains, Bloomquist and Eipper 1991) further studied the rate limiting 
role of PAM in the biosynthesis of α-amidated peptide hormones by manipulating its 
expression level in AtT-20 cell line. Model cell lines with significantly increased or 
decreased level of PAM were generated by transfection with vectors containing PAM 
cDNA in the sense or antisense orientation. In wild type AtT-20 cells, concentration of 
 11 
 
newly synthesized joining peptide in amidated form (JP) is close to that in 
glycine-extended form (JP-Gly). Cells expressing increased level of PAM produced 
almost entirely JP while cells with decreased PAM level produced half as much JP as 
wild type cells (Mains et al. 1991). 
1.1.2.4 Accumulation of glycine-extended precursor by PAM inhibition. 
Since PAM is the only enzyme catalyzing the amidation reaction and functions as the 
rate limiting role, accumulation of glycine-extended precursor peptides can be achieved 
by reducing its activity. In mouse pituitary cancer cell line AtT-20, over half of joining 
peptide is α-amidated. When incubating with 0.5 µM or 2.0 µM metal chelating reagent 
disulfiram, percentage of newly synthesized joining peptide in amidated form decreased 
to 15% and10%, respectively (Mains, Park and Eipper 1986). Similar experiments have 
been done in vivo with rats in which significant accumulation of glycine-extended 
precursors was also observed (Marchand et al. 1990, Mains et al. 1986). PAM activity 
level can also be regulated by modulating its expression level using anti-sense RNA 
which also results in accumulation of glycine-extended precursors (Mains et al. 1991).  
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1.2 Current Method to Identify α-Amidated Peptides 
Peptide amidation has been termed “signature of bioactivity” because most known 
α-amidated peptides are bioactive (Cuttitta 1993). Efforts have been made to discover 
novel peptide hormones through identification of peptides with C-terminal amide. 
1.2.1 Chemical assay methods. 
1.2.1.1 Tatemoto & Mutt method.  
In this method, the target peptide was proteolytically fragmented to a mixture of short 
peptides, amino acids, and the single C-terminal amino acid amide which could be 
extracted from the mixture and identified. This approach was pioneered by Tatemoto & 
Mutt (Tatemoto and Mutt 1978) in the late 1970’s and was used to identify a number of 
important α-amidated peptide hormones, including galanin (Tatemoto et al. 1983) and 
pancreastatin (Tatemoto et al. 1986). In the original Tatemoto & Mutt method, the 
degradation mixture (consisting of peptide fragments, amino acids and an amino acid 
amide) was dansylated. The hydrophobic dansyl-amino acid amide was extracted into an 
organic phase followed by two-dimensional TLC identification. With the improvement in 
separation and detection of C-terminal amino acid amide using HPLC (Simmons and 
Meisenberg 1983, Schmidt et al. 1987) and capillary electrophoretic chromatography 
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(Feng and Mitchell 1999), the limit of detection for this method was decreased from 
approximately 1 nmol to picomole range in model studies using purified α-amidated 
peptides or amino acid amides. However, when dealing with complex samples, 
inefficiency in the proteolytic fragmentation, in the labeling chemistries, and in the 
extraction or separation of the amino acid amide (or its derivative), can dramatically 
decrease the sensitivity. Moreover, this method can only tell the presence or absence of 
α-amidated peptides. Further fractionation/purification would be needed to identify 
peptides of interest. Although being used for identification of a few α-amidated peptide 
hormones, the Tatemoto & Mutt procedure has not been widely used to discover novel 
peptide hormones, but to characterize the C-terminal amidated amino acid after the 
purification of new bioactive peptide (Carlquist, Mutt and Jornvall 1979, Carlquist, 
Jornvall and Mutt 1981). 
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Figure 4.  Schematic of Tatemoto & Mutt Mehod. 
The target peptide was proteolytically degraded to single amino acids or short peptides. 
Resulted mixture was dansylated using amine labeling. Under alkaline conditions, the 
hydrophobic dansyl-amino acid amide was extracted into an organic phase and identified 
with 2D TLC. 
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1.2.1.2 Hill method. 
Hill et al. (Hill, Flannery and Fraser 1993) presented a different chemical approach 
for the identification of α-amidated peptides in a complex mixture of peptides from a 
biological source. Free amines in the peptides were first protected by acetylation. Next 
the amides were converted to amines via Hofmann rearrangement. The newly formed 
amines were detected by labeling with ninhydrin. Another reaction for detection of 
glycine-extended peptides was also developed in which the C-terminal glycine was 
derivatized to form 2-thiohydantonin. Peptides with C-terminal amide or C-terminal 
glycine derivatives were detected by HPLC. Hill et al. (1993) argued that the co-elution 
of the amide and a C-terminal glycine was a strong indicator for the presence of an 
α-amidated peptide. Overall, the Hill method is very laborious, insensitive (mmol 
detection limit), and prone to false positives from peptides with Asn and Gln residues. 
These drawbacks have dramatically hindered the widespread application of this method, 
as it has never been used for the discovery of novel α-amidated peptide. 
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Figure 5.  Schematic of Hill Method. 
Following the protection of peptide free amines by acetylation, the C-terminal amide was 
converted to amine by Hoffman rearrangement and then colorized by ninhydrin.  
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1.2.1.3 Carpenter & Merkler method. 
Carpenter & Merkler method (Carpenter 2006) was developed based on the detection 
of the PAM reaction by-product glyoxylate. In this method, PAM inhibitor was used in 
cell culture to accumulate glycine-extended peptides.  Total peptides were then 
extracted from cells and chromatographically fractionated. The resulting fractions were 
treated with PAM to convert glycine-extended peptides, if any, to the α-amidated 
peptides and glyoxylate. The glyoxylate produced in PAM reaction was then quantified 
using either a spectrophotometric, fluorescent, or chemiluminescent enzyme linked assay 
(Figure 6). The most sensitive assay for glyoxylate was the chemiluminescent assay 
which linked the glyoxylate consumption to light emission through hydrogen peroxide. 
The detection limit was claimed to be 5 nM for hydrogen peroxide and 15 nM for 
glyoxylate. However, when handling samples from biological sources, this method 
suffered severe background problem due to the complexity of the samples. The signal to 
noise ratio was below 25 even for the model α-amidated peptide with high concentration.  
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Figure 6.  Schematic of Carpenter & Merkler method. 
A: PAM reaction to convert accumulated glycine-extended peptide to α-amidated peptide 
and glyoxylate. B: The malate synthase / malate dehydrogenase assay. Tetrazolium was 
oxidized to yield a formazan dye through an electron shuttling pathway with the 
concomitant reduction of NAD. Formazan can be detected at 490nm. C: The glyoxylate 
reductase assay. Glyoxylate was detected by monitoring NADPH loss at 340nm. D: 
Hydrogen peroxide assay. Hydrogen peroxide was stoichiometrically produced by 
glycolate oxidase from glyoxylate. Three approaches were presented for the detection of 
hydrogen peroxide in which hydrogen peroxide consumption was linked to the 
production of indamine dye (λmax=590 nm), fluorophore resorufin (λex=560 nm, λem=589 
nm) or light. 
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1.2.2 Immunoassay methods. 
A possible method to identify α-amidated peptides would be the use of antibodies to 
specifically recognize a C-terminal amino acid amide. To date, no antibody has ever been 
developed to recognize a single amino acid amide. However, the Grimmelikhuijzen 
group has produced an antibody against dipeptide amide, Arg-Phe-NH2, and used this 
antibody for the discovery of a number of novel α-amidated peptides (Grimmelikhuijzen 
and Graff 1985, Grimmelikhuijzen, Leviev and Carstensen 1996, Grimmelikhuijzen, 
Williamson and Hansen 2002). High quality antibodies against all possible dipeptide 
amides, a library of 400 antibodies, will be required for a broad application of this 
approach for the discovery of novel α-amidated peptides.   
1.2.3 Mass Spectrometry Based Methods. 
1.2.3.1 Mass difference based method. 
The mass difference between the C-terminal amino acid amide and its cognate free 
carboxylate form is 0.9840 Da. The combination method of carboxypeptidase Y digestion 
and fast atom bombardment (FAB) mass spectrometry was developed to exploit this mass 
difference to identify α-amidated peptides (Kim and Kim 1994). In this method, target 
peptide was digested for various times and the digestion products analyzed using FAB 
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mass spectrometer. From the mass difference between the parent peptide and its 
one-amino-acid-short fragment, the identity of the C-terminal residue can be readily 
determined. Sequence information can also be obtained from mass differences of 
consecutive digestion products. The limitation of this method is that some amino acids 
have same or very close mass value and, thus, cannot be distinguished from each other. 
Examples include the exact same masses for Leu and Ile, and Glu-amide and Gln, and 
millimass differences between Lys and Gln, Asn-amide and Leu/Ile, and Glu-amide and 
Lys. Moreover, this method works best with purified peptide. 
The small mass difference between peptides with C-terminal amide and free 
carboxylic acid can be amplified through derivatizations. Kuyama et al. (2009) presented 
a chemical approach to convert the free C-terminal carboxyl group to methylamide 
(CONHCH3) via oxazolone chemistry. This method targets only the C-terminal carboxyl 
group while free carboxyl side chains in Asp and Glu remain intact (Kuyama et al. 2009). 
Due an incomplete derivatization, peptides with free C-terminal carboxylate exhibit 
doublet peaks in MS spectra separated by 13 Da (the difference between COOH and 
CONHCH3), while α-amidated peptides show normal singlet peaks, as such peptides 
have a protected C-terminus. 
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1.2.3.2 Fragmentation behavior based method. 
It was reported that α-amidated peptides demonstrated specific fragmentation patterns 
under tandem mass spectrometry (MS/MS). Mouls et al. (Mouls et al. 2006) investigated 
the behavior of α-amidated and normal peptides upon low energy collision-induced 
dissociation (CID) and found amidated peptides produced an abundant loss of ammonia 
from protonated molecules. The side chain amides as in Asp and Gln were found much 
more stable than C-terminal amide under the CID conditions and, thus, did not affect the 
detection of α-amidated peptides. Lys and Arg at the C-terminus were stable at the CID 
conditions. However, ammonia loss from the side chain of Arg residues within peptide 
chains was observed. This method is useful to identify α-amidated peptides from trypsin 
digested products, which have all the Arg residues present at C-terminus. Significant 
false positives from internal Arg residues would show up when handling non-tryptic 
peptides. CID energy levels required to generate maximal ammonia loss vary from 17% 
to 80% (normalized energy level), based on the length and amino acid composition of the 
peptide. This could restrict this method as screening strategy from a complex peptide 
mixture.  
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1.2.3.3 Tandem mass spectrometry coupled with database search. 
Liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) followed 
by database search has been emerged as a powerful tool for peptide identification due to 
its advantages of speed, sensitivity, and applicability to complex peptide mixtures. A few 
α-amidated peptides have been recently discovered using this method, such as the 
C-terminal fragments of chromogranin A ER-20amide and AR-28amide (Taylor et al. 
2006), as well as the neuroendocrine regulatory peptides NERP-1 and NERP-2 
(Yamaguchi et al. 2007). 
In a general LC-MS/MS process, the peptide mixture is loaded onto a reverse phase 
LC column and fractionated based on peptide hydrophobicity. For on-line LC-MS/MS, 
eluted peptides are usually electrosprayed directly into a mass spectrometer and 
transferred into ionized form in the gas phase. Masses of peptides are collected and 
recorded in a MS spectrum. One peptide ion (called parent ion) at a time is selected and 
isolated for fragmentation to generate the MS/MS spectrum. Shown in Figure 7 are 
nomenclatures for common peptide fragment ions (Roepstorff and Fohlman 1984) . In 
many mass spectrometry instruments, the major peaks in an MS/MS spectrum are b ions 
and y ions, where the charges are retained on the N-terminus and C-terminus, 
respectively. Depending on the fragmentation technique, the mass analyzer, and the 
 23 
 
peptide structure, other type of ions could be dominant, as well. An example is electron 
capture dissociation (ECD) which produces mainly c- and z-type ions. The MS and  
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Figure 7.  Nomenclature for fragment ions in mass spectra of peptides.  
a-, b- and c-type ions are N-terminal ions; x-, y- and z-type ions are C-terminal ions. R1, 
R2, R3 and R4 represent the side chains of different amino acids. 
MS/MS spectra are written to a “raw file” in a certain format. One raw file normally 
contains thousands to hundreds of thousands spectra depending on the complexity of the 
sample, the LC settings, and the mass spectrometer conditions. 
Mapping MS/MS information to peptide sequences is usually done by database 
search engines such as MASCOT (Perkins et al. 1999), SEQUEST (Yates et al. 1996) 
and X!TANDEM (Craig and Beavis 2004). In general, the search engine generates all 
possible peptide sequences (predicted peptides) from a protein database into an indexed 
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list. By matching masses of predicted peptides and the observed mass of the experimental 
peptide, possible candidate peptide sequences are selected. Then, theoretical fragment 
ions are generated from these sequences and compared with the MS/MS spectrum of the 
experimental peptide for scoring. The search engine ranks the score of all candidates and 
reports back the top ranked hit or multiple matches (SEQUEST). 
MS/MS spectra can also be interpreted through de novo sequencing, i.e. sequencing 
without assistance of a linear sequence database (Seidler et al. 2010). De novo 
sequencing can be done manually by comparing mass differences between fragment ions 
and theoretical masses of amino acid residues. An example of manual de novo 
sequencing of an α-amidated peptide found in AtT-20 cell line is shown in Figure 8. 
Software have also been developed to automate this approach such as PEAKS (Ma et al. 
2003), DeNovoX (Thermo, San Jose, CA, USA), PepNovo (Frank and Pevzner 2005) and 
Vonode (Pan et al. 2010). In spite of the continuous growing of protein/genome sequence 
databases, de novo sequencing is still essential in some situations such as identification of 
protein/peptide from organisms with unsequenced genomes and protein/peptide with 
non-proteinogenic amino acids or unknown PTMs. 
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Figure 8.  The de novo sequencing of a peptide. 
Mass differences between a set of fragment ions (b ions, marked with red lines) were 
used to identify the individual amino acids and the peptide sequence. The same sequence 
was deduced from the other set of fragment ions (y ions, marked with blue lines), which 
is highly suggestive that the sequence is the actual one.  
1.3 Introduction to a Novel Strategy for the Discovery of Novel α-Amidated Peptides 
1.3.1 Impetus for the design of an efficient and effective α-amidated peptide 
screening method. 
The only known physiological function of PAM is to convert glycine extended 
prohormones (including glycine-extended peptides and fatty acyl-glycine) to their 
amidated forms. No evidences have been found to suggest any other biological role of 
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PAM or to explain the presence of PAM in tissues not known to produce α-amidated 
products. Moreover, high levels of PAM were found in certain tissues with no 
corresponding level of known amidated products. One example is the relatively high 
level of PAM expression in the cardiac atrium (Eipper et al. 1992), yet only minor levels 
of α-amidated peptides have been detected from this tissue. Therefore, it is believed that 
there are as yet undiscovered α-amidated peptide hormones in certain tissues.  
To date, there has been no detection method capable to screen for every existing 
α-amidated peptide in every tissue. Known α-amidated peptides were discovered by a 
variety of techniques. Some of them were found by coincidence. The lack of systematic 
screening method strengthens the hypothesis that there are many undiscovered 
α-amidated peptides. 
Reported methods for the identification of α-amidated peptides were summarized and 
discussed in section 1.2 in this chapter. Of these methods, the most promising one to 
screen for novel α-amidated peptides is LC-MS/MS coupled with database search. 
Advancement in mass spectrometry provides instruments with high resolution and 
sensitivity. LC or 2D LC systems coupled with mass spectrometers makes it possible to 
handle complex biological samples. However, several drawbacks need to be overcome in 
order to apply this method to high throughput screening for novel α-amidated peptides.  
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With automatic spectra interpretation through database search, only as low as around 
10% spectra can be successfully mapped (Keller et al. 2002). Moreover, when handling 
endogenous peptide identification, database searching is extremely time-consuming since 
all possible cleavage sites must be considered (i.e. “no enzyme” setting has to be chosen) 
and multiple PTMs must be selected to enhance the successful identification rate (Falth et 
al. 2006). The expansion of searching space resulted from this settings will in turn 
generate more false positives. 
1.3.2 Novel LC-MS/MS based α-amidated peptide screening strategy. 
In biological tissues, α-amidated peptides are surrounded by an ocean of various 
peptides, modified and unmodified, signal peptides and protein degradation fragments. 
Modern mass spectrometers coupled to the appropriate separation techniques are capable 
of identifying parent ion signals of peptides at very low concentration and obtaining their 
MS/MS spectra. However, high quality MS/MS spectra are not guaranteed, especially for 
peptides with low abundance and/or PTMs. Screening for α-amidated peptides from large 
number of MS/MS spectra of all kinds of peptides is akin to finding "needles in a 
haystack". In this study, we attack this problem from two angles, reducing the haystack 
and making the needles larger. 
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1.3.2.1 Peptide pair strategy to reduce the haystack. 
As shown in Figure 3, the glycine-extended precursor loses a [C2H3O2] group from 
C-terminal and gains one proton on the terminal α-amide during the PAM catalyzed 
amidation reaction, resulting in a total difference of 58.0055 Da (C2H2O2) between the 
glycine-extended and amidated forms. Since an α-amidated peptide and its 
glycine-extended precursor have identical amino acids sequences except the relatively 
small difference at the C-termini, they will have similar hydrophobicities, similar reverse 
phase retention times, and similar MS/MS fragmentation patterns. By finding peptide 
pairs which meet these criteria, one can screen for amidated peptides from LC-MS/MS 
data. A script was developed to scan peptide parent ions in LC-MS/MS data for peptide 
pairs with 58 mass unit difference and similar retention times. Fragmentation patterns of 
the two MS/MS spectra in each pair were checked for similarity to validate if these were 
related α-amidated and glycine-extended peptides. Only peptide pairs which met all three 
criteria were considered for further interpretation. Thus the haystack, namely amount of 
MS/MS spectra to be interpreted, was greatly reduced.  
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1.3.2.2 α-Amidated peptide enrichment to enlarge the needles. 
Copper-depleted PHM (apo-PHM) was used to enrich α-amidated peptides from a 
complex mixture. When incubating apo-PHM with peptide mixtures, glycine-extended 
peptide substrates bound to PHM. After the removal of the unbound peptides, PHM was 
reactivated by addition of copper to release the bound glycine-extended peptides as these 
were oxidized to the α-hydroxyglycine peptide products. The hydroxylated intermediates 
were then converted to the α-amidated products by adjusting pH > 10 (Jones et al. 1988). 
As a result, the relative concentrations of α-amidated peptides were significantly 
increased. 
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Chapter 2 Peptide-pair Screening Strategy for the Discovery of α-Amidated 
Peptides 
2.1 Introduction 
A modified peptide and its unmodified counterpart have identical sequences with the 
only difference being the modified amino acid(s). Thus, modified and unmodified forms 
of a peptide have a specific mass difference, similar reverse phase retention times, and 
similar MS/MS fragmentation patterns.  
For a certain PTM, the mass differences between modified peptides and their 
unmodified forms are specific and constant. Based on this, a tool named Mass Distance 
Fingerprint (MDF) (Potthast et al. 2007) was developed to detect predominant PTMs.  
Mass Distance Histogram (MDH) was first established by calculating peptide distances 
(mass differences) of all peptide pairs. A statistical random background model was then 
subtracted from the MDH. The Gaussian distributions were fitted to the remaining data to 
obtain accurate frequent mass distances, which imply modification(s). This method only 
uses peptide precursor mass and is not database dependent. Therefore, it is rapid and can 
detect unknown PTMs. However, this method is not capable of detecting less abundant 
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modifications because both modified and unmodified forms of the peptide must be 
measured for multiple times in order to yield a reasonable signal above background. 
Retention time difference could provide orthogonal supporting evidence for 
PTM-related peptide pairs. Fu et al. (Fu et al. 2009) presented a sequence 
database-independent approach to detect abundant PTMs in high-accuracy peptide mass 
spectra. This approach was based on the assumption that a modified peptide and its 
unmodified form correlate with each other in masses and retention times. Mass 
differences and retention time differences between spectra were plotted on a 2D 
histogram followed by a bivariate Gaussian mixture model to differentiate modification 
related pairs and random pairs. Frequently occurring peptide pairs with same mass and 
retention time differences indicated a modification. This method used parent ion masses 
and retention times to scan the LC-MS/MS data and, hence, was rapid. However, it was 
designed only to detect abundant PTMs which are found in large number of spectra in 
order to be discriminated from random spectra pairs. 
In addition to mass and retention time differences between parent ions, related 
fragment ions were also used in a similar approach reported by Savitski et al. (Savitski, 
Nielsen and Zubarev 2006). Savitski et al. only plotted spectral pairs with similar MS/MS 
spectra, in contrast to the approach of Fu et al., which plotted all combinations of the 
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mass retention time differences for all spectral pairs. The similarity was defined as at 
least four matching fragment pairs in two MS/MS spectra. Matching fragment pairs were 
either a pair of fragment ions with the same mass, or with a mass difference the same as 
that of the two parent ions. Both collision induced dissociation (CID) and electron 
capture dissociation (ECD) were used to get complementary fragmentation. This method 
is more sensitive for the detection of PTMs relative to the Fu et al. approach, but at a cost 
of computational efficiency and additional instrumentation. However, spectral pairs with 
certain PTM still must be identified multiple times for statistical significance. Moreover, 
multiple fragmentation methods were required, which often cannot be done in many 
proteomic labs.  
When considering the identification/detection of peptides with a known modification, 
more restrictive screening conditions can be implemented. Instead of statistically 
analyzing mass differences between all peptide pair combinations, one could just look for 
peptide pairs with the known mass difference. α-Amidated peptides differ from their 
corresponding glycine-extended precursors with a mass difference of 58.0055 Da 
(C2H2O2), as a consequence of the PAM-catalyzed amidation reaction. α-Amidated 
peptides and the glycine-extended precursors have identical amino acid sequences except 
for the small difference at their respective C-termini. Therefore, they have similar 
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hydrophobicities, reverse phase retention times, and MS/MS fragmentation patterns.  
Moreover, the enzyme responsible for the peptide amidation (PAM) is well studied and 
inhibitors are available. The application of PAM inhibitors leads to the accumulation of 
glycine-extended precursors, which can be used not only to insure the coexistence of 
α-amidated peptides and their glycine-extended precursors, but also to provide another 
restriction for screening. 
2.2 Material and Methods 
2.2.1 Materials. 
The mouse pituitary AtT-20 cell line and basal F-12K medium (Kaighn's 
Modification of Ham's F-12 Medium) were from American Type Culture Collection 
(www.atcc.org). Fetal bovine serum (FBS) was from Atlanta Biologicals. Donor equine 
serum was from Thermo Scientific.  Mouse pituitaries were from Pel-Freez Biologicals. 
Disulfiram (1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane) was from 
Fluka. CHCA (α-cyano-4-hydroxycinnamic acid) and adenosine 5′-triphosphatase 
(ATPase) from porcine cerebral cortex were from Sigma-Aldrich. Pen-Strep was 
purchased from Omega Scientific. Angiotensin-converting enzyme (ACE) was from MP 
Biomedicals.  Mouse joining peptide (mJP) and its glycine extended precursor form 
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(mJP-Gly), the α-amidated peptide ELEGERPL-NH2, and a glycine-extended peptide 
QNEWRIPG were synthesized in-house at the USF Core Peptide Synthesis and Mass 
Spectrometry Facility. Sep-Pak Plus C18 cartridges were from Waters Associates.  
ZipTips were from Millipore.  All other reagents and solvents were of the highest 
quality commercially available. 
2.2.2 Cell growth conditions. 
Mouse pituitary AtT-20 cells were cultured in Hams F-12K culture medium 
supplemented with 15% (v/v) horse serum, 2.5% (v/v) fetal bovine serum and 1% (v/v) of 
the antimicrobial Pen-Strep (10,000 units Penicillin (Base)/mL and 10,000 units 
Streptomycin (Base)/mL in 0.85% NaCl). Cells were grown in 225 cm2 culture dishes in 
the presence of 5% CO2 at 37 ºC. The AtT-20 cell line was non-adherent. The cells were 
passed at 1:3 into fresh media after 80% confluence was reached in each culture flask.  
A class II sterile laminar flow hood was utilized for all cell culture work. Cells were 
cultured in a 37ºC incubator with a constant flow of 5% CO2. After sufficient growth, 
cells were collected by centrifugation and evenly split into two 225 cm2 culture dishes 
containing 75 mL fresh media. A 75 µL aliquot of 5.0 mM disulfiram (prepared in 70% 
ethyl alcohol) was added to one dish to bring the final disulfiram concentration to 5 µM. 
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An equivalent volume of 70% (v/v) ethanol (vehicle) was added to the other dish as 
control. The cells were incubated for 20 hours prior to harvest. 
2.2.3 Sample preparation. 
2.2.3.1 Total peptide extraction. 
Cells were collected by centrifugation. The spent media was acidified to 0.1% (v/v) 
TFA with a 6% TFA stock and centrifuged at 12000g for 30 minutes. The cell pellet was 
homogenized in a ground glass homogenizer at 4 ºC with 8 M urea solution or acid 
extract solution containing 0.1M HCl, 5% (v/v) formic acid, 1% (w/v) NaCl and 1% (v/v) 
TFA (Bennett, Browne and Solomon 1981). The homogenate was centrifuged at 12000g 
for 15 minutes. The supernatant was collected and added to the acidified media. The 
mixture was passed through 10 kDa molecular weight cut-off filter (Microcon YM-10, 
Millipore, Bedford, MA, USA) to remove proteins.  
A total of 5 mouse pituitary glands (Pel-Freeze Biologicals, Rogers, AR, USA) were 
cut into small pieces and homogenized in a ground glass homogenizer at 4ºC using an 
acid extract solution containing 0.1M HCl, 5% (v/v) formic acid, 1% (w/v) NaCl and 1% 
(v/v) TFA. The homogenate was centrifuged at 12000g for 15 minutes. The supernatant 
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was collected and passed through a 10 kDa molecular weight cut-off filter to remove 
proteins.  
2.2.3.2 Solid phase extraction. 
The peptide extract was initially desalted and concentrated by solid phase extraction 
on a C18 cartridge (Sep-Pak Plus, Waters, Milford, MA, USA). A Sep-Pak Plus cartridge 
was pre-wetted with 10 mL of a solution composed of 0.1%(v/v) TFA/80%(v/v) 
acetonitrile (ACN) at a flow rate of 2.0 mL/min. The cartridge was then washed with 20 
mL aqueous solution of 0.1% (v/v) TFA/2%(v/v) ACN at a flow rate of 2.0 mL/min. The 
peptide extract was loaded onto the cartridge at a rate of 1.0 mL/min, followed by a wash 
of 20 mL of 0.1% TFA (v/v) /2%(v/v) ACN at a flow rate of 1.0 mL/min.. Bound 
peptides were eluted with 4 mL of 0.1% (v/v) TFA/80% ACN at a flow rate of 1 mL/min.  
The 4 mL eluent was collected and concentrated to 0.5 mL on a Savant Speedvac vacuum 
centrifuge (Savant Instruments, Farmingdale, New York, USA). 
Prior to LC-MS/MS analysis, the extracted peptide mixture was further purified using 
ZipTip(Millipore, Billerica, MA, USA). A ZipTip was wetted by aspirating 10 µL of 
methanol and dispensing it to waste 10 times followed by 0.1% (v/v) TFA/80% ACN for 
8 times. The ZipTip was then equilibrated with 0.1% (v/v) TFA/2% ACN 6 times by 
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aspirating and dispensing. Peptides were bound by aspirating 10 µL of the peptide 
mixture solution and dispending it back for 15 cycles. After 10 cycles wash using 0.1% 
(v/v) TFA/2% ACN, bound peptides were eluted by 10 µL of 0.1% (v/v) TFA/80% ACN. 
Elution was repeated twice with fresh eluting solution. A total of 30 µL of eluent was 
obtained and concentrated on the Speedvac to 5 µL. 
2.2.4 LC-MS/MS assay. 
The sample was analyzed by matrix assisted laser desorption ionization – time of 
flight (MALDI-TOF) mass spectrometer and linear ion trap-Orbitrap mass spectrometer 
(LTQ-Orbitrap). For MALDI-TOF assay, samples from disulfiram treated group and 
control group were analyzed separately in order to get peptide intensity information so 
that accumulation filter can be applied when processing data. For LTQ-Orbitrap assay, 
samples from the two groups were combined and analyzed together.  
2.2.4.1 LC-MALDI-TOF/TOF 
The sample subject to MALDI-TOF assay was fractionated and spotted onto 192-well 
plates using a microfraction collector (LC Packings Probot, Dionex, Sunnyvale, CA, 
USA) interfaced with a capillary liquid chromatograph (Agilent 1200, Agilent, Santa 
Clara, CA, USA). The sample was loaded on a C18 column (100 mm × 150 µm ID, Vydac 
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MS C18, Grace, Deerfield, IL, USA) and washed for 20 minutes with 95% solvent A (2% 
ACN + 0.1% TFA)and 5% solvent B (80% ACN + 0.1% TFA). The 65-minute gradient 
was programmed as: 5% to 15% B in 10 minutes, 15% to 50% B in 40 minutes, 50% to 
90% B in 5 minutes, 90% B for 5 minutes and 90% to 5% B in 5 minutes. The flow rate 
was 1 µL/min. Separated peptides were mixed with α-cyano-4-hydroxycinnamic acid 
solution (4mg/mL in 50%( v/v) ACN and 5% (v/v) isopropanol) delivered at a flow rate 
of 1.0 µL/min. Fractions were spotted every 15 s onto blank stainless steel MALDI plates 
(Applied Biosystems, Foster City, CA, USA). 
Spotted peptide fractions were analyzed by MALDI-TOF/TOF mass spectrometry 
(Applied Biosystems 4700 Proteomics Analyzer, Foster City, CA, USA) using reflective 
positive mode. MS spectra were obtained with a total of 1500 shots per spot. Up to the 10 
most intense precursors per spot were then selected for MS/MS analysis. MS/MS spectra 
were generated with a total of 5000 shots for each precursor. The data was externally 
calibrated with 4700 Mass Standards from the manufacture. 
2.2.4.2 LC-ESI-LTQ-Orbitrap 
A nanoflow liquid chromatograph (U3000, Dionex, Sunnyvale, CA, USA) was 
coupled to an LTQ-Orbitrap (Thermo, San Jose, CA, USA).  The LC system was 
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equipped with a trapping column (5mm x 300 µm ID packed with C18 reversed-phase 
resin, 5µm, 100Å) and an analytical column (C18, 150 mm × 75 µm ID, Pepmap 100, 
Dionex, Sunnyvale, CA, USA). The sample was first loaded onto a trapping-column and 
washed for 8 minutes with aqueous 2% ACN and 0.04% TFA. Trapped peptides were 
then eluted onto the analytical column. The 120-minute gradient was programmed as: 5% 
B for 8 minutes, 5-50% B in 90 minutes, 50-90% B in 7 minutes, 90% B for 5 minutes, 
90-5% B in 1 minute and 5% B for 10 minutes to re-equilibrate, with solvent A being 2% 
ACN + 0.1% formic acid and solvent B being 90% ACN + 0.1% formic acid. The flow 
rate on the analytical column was 300 nL/min. (1/1000 split from 300 µL/min.) Peptides 
eluted were electrosprayed directly into an LTQ-Orbitrap mass spectrometer. Survey 
scans were performed in Orbitrap to obtain accurate peptide mass measurement. The 
resolution was 60,000 at 400 m/z. Mass measurement accuracy was monitored between 
runs using digested BSA. For each cycle of the survey scan, the five most intense 
precursor ions were selected for MS/MS analysis. MS/MS spectra were acquired in linear 
ion trap with normalized CID energy of 30%. Previously selected precursor ions were 
dynamically excluded for 60 seconds.   
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2.2.5 LC-MS/MS data processing. 
2.2.5.1 LC-MALDI-TOF/TOF data processing. 
Mass lists of each MS spectrum (from both disulfiram treated and control group) 
obtained by MALDI-TOF were exported and combined into one Excel data sheet. The 
complete list was then imported into Microsoft Visual FoxPro 8.0. Peptides with mass 
difference smaller than 0.1 m/z and a retention time difference under 2 minutes were 
considered the same peptide. The peptide with highest intensity was kept and all others 
were removed from the list. After removal of redundant data, the list was scanned for 
peak pairs with 58.01 ± 0.1 m/z difference and a retention time difference less than 2 
minutes. Accumulation filter was then applied. Only peptides showing higher intensity in 
disulfiram-treated group were kept. The signal-to-noise (S/N) filter was also used to filter 
out less intensified peptides. Peaks in resulted peak-pairs were subjected to MS/MS 
analysis. The MS/MS spectra of each pair were inspected manually for similar fragment 
patterns. Interesting MS/MS spectra were sequenced by database search and/or manual 
interpretation. 
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2.2.5.2 LC-ESI-LTQ-Orbitrap data processing. 
Information of MS/MS spectra was extracted from RAW data files obtained from 
LTQ-Orbitrap using RawXtract1.93 (Thermo Corp., San Jose, CA, USA). The list, which 
contains detailed information of each MS/MS spectrum such as scan number, charge state, 
monoisotopic m/z and retention time, was imported to Microsoft Visual FoxPro 8.0. 
Peptides with mass difference smaller than 0.005 m/z and retention time difference under 
2 minutes were considered the same peptide and only one was kept for further processing. 
After removal of redundant data, the list was scanned for peak pairs with mass difference 
of 58.006 ± 0.01 (for singly charged ions), 29.003 ± 0.01 (for doubly charged ions) and 
19.335 ± 0.01 (for triply charged ions), and retention time differences within 2 minutes. 
The MS/MS spectra of each pair were inspected manually and interesting spectra were 
sequenced by database search and/or manual interpretation. 
2.2.6 ATPase activity assay. 
The effects of mouse joining peptide (mJP) and two mJP related peptides on ATPase 
activity were tested. The standard ATPase activity assay was carried out at 37 ºC by the 
addition of enzyme into 1.5 mL solution containing 20 mM Tris-HCl, pH 7.8, 0.57 mM 
EDTA, 5 mM MgCl2, 3 mM KCl, 133 mM NaCl and 2.67 mM ATP (tris salt). After 20 
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minutes incubation, 1.5 mL of 20% (w/v) trichloroacetic acid (TCA) was added to stop 
the reaction. The mixture was centrifuged at 12000g for 3 minutes to clarify. To measure 
the phosphate concentration from ATPase hydrolysis, the supernatant (1 mL) was mixed 
with 2 mL Taussky-Shorr reagent and 1 mL distilled water, the mixture was incubated at 
25 ºC for 5 minutes, and the absorbance at 660 nm was then measured.  
Taussky-Shorr reagent was prepared as follows: 2 g of ammonium molybdate was 
dissolved in 5 M H2SO4 to a final volume of 20 mL. Distilled water (140 mL) was added 
followed by the addition of 10 g ferrous sulfate heptahydrate. The solution was brought 
to a final volume of 200 mL with water.  
Standard curve was established by mixing 2 mL Taussky-Shorr reagent, 1 mL of 
phosphorus standard with a variety of concentration, 0.5 mL of 20% (w/v) TCA and 0.5 
mL distilled water, and incubating for 5 minutes followed by absorbance measurement at 
660 nm. 
2.2.7 Angiotensin converting enzyme activity assay 
Angiotensin converting enzyme activity assay was carried out at 37 ºC by the addition 
of 0.01 unit enzyme into a 0.25 mL reaction mix containing 40 mM HEPES, pH 8.3, 240 
mM sodium chloride, 0.2% (w/v) hippuryl-L-histidyl-L-Leucine (HHL). The reaction 
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mixture was incubated for 20 minutes. An aliquot of 1 M HCl (0.25 mL) was then added 
to quench the reaction. After a 10 minute centrifugation at 12000g, 10 µL of the 
supernatant was injected to HPLC (Hewlett Packard series 1100 HPLC, Hewlett-Packard, 
Wilmington, DE, USA ) to quantify the amount of enzymatically produced hippuric acid .  
Reaction mixture was separated on a reverse-phase C18 column (Hypersil ODS, 4.6 × 
100 mm, 5 µm, Keystone Scientific, Inc., Bellefonte, PA). Isocratic elution for 4 minutes 
with 15% (v/v) ACN aqueous solution was followed by a 4 minute wash run with 65% 
(v/v) ACN. Hippuric acid eluted at 2.5 min. HHL and L-histidyl-L-leucine eluted during 
wash run. Eluent was monitored with UV detector at 228 nm.  
Standard curve for hippuric acid measurement was established by injecting10 µL of 
hippuric acid with a variety of concentration into the HPLC system. 
2.3 Results 
2.3.1 Proof of concept.  
Mouse pituitary corticotropic tumor AtT-20 cells are known to express high levels of 
PAM and two α-amidated peptides: mouse joining peptide (mJP) and α-melanotropin 
(α-MSH) (Eipper et al. 1986). For proof of concept, the accumulation of 
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glycine-extended precursors of these two known peptides was investigated, as well as 
retention time and mass differences between the two amidated peptides and their 
precursors, and their fragmentation patterns under CID. 
2.3.1.1 Accumulation of glycine-extended precursors. 
PAM activity in AtT-20 cells can be inhibited using the copper chelators, disulfiram, 
resulting in the accumulation of glycine-extended precursors (Mains et al. 1986). The 
relative levels of these peptides in cells grown with and without PAM inhibitor were 
investigated using LC-MALDI-TOF. As shown in Table 3, the relative intensity of 
glycine-extended precursors (in comparison with intensity of amidated form) increased 
by 2.8-fold for mJP and 9.2-fold for α-MSH when treated with PAM inhibitor.  
Table 3.  Accumulation of glycine-extended precursors of two known amidated 
peptides. 
 Control Disulfiram treated  
 Amidated Gly-extended Amidated Gly-extended Accumulation 
Mouse joining peptide 2780 5400 1240 6700 2.8 
α-Melanotropin 3750 3100 1300 9940 9.2 
Numbers denote the peak intensity of a peptide except in the last column. Numbers in the 
last columns denote folds of accumulation of corresponding α−amidated peptide in 
disulfiram treated group. 
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2.3.1.2 Retention time. 
Retention times of mJP and α-MSH were very close to their glycine-extended 
precursors as shown in Table 4. Under LC conditions for Orbitrap analysis, retention time 
differences between amidated and glycine-extended peptides were 0.86 minutes and 0.9 
minutes for mJP and α-MSH, respectively. Extracted ion chromatograms (XIC) of these 
4 peptides are also shown in Figure 9. 
Table 4.  Retention time differences between the two known α−amidated 
peptides and their glycine-extended precursors. 
 Average ∆RT(min) St. Dev. 
Mouse joining peptide 0.86 0.01  
α-Melanotropin 0.9 0.3  
RTs are based on the LC conditions as specified in section 2.2.4.2. Values were 
calculated from 3 readings. 
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Figure 9.  XICs of mJP, α-MSH and their glycine-extended precursors. 
A: mJP-Gly; B: mJP; C: α-MSH-Gly; D: α-MSH. The retention time difference between 
mJP and mJP-Gly was 0.86 minutes. The retention time difference between α-MSH and 
α-MSH-Gly was 0.64 minutes. 
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2.3.1.3 Observed mass difference. 
Observed masses of two known α−amidated peptides and their glycine-extended 
precursors were investigated with TOF and Orbitrap mass analyzers. Shown in Table 5 is 
the distribution of observed masses of the four peptides obtained by TOF mass analyzer. 
Observed mass difference between mJP and mJP-Gly ranged from 57.9228 to 58.1116 
while that of α-MSH and α-MSH-Gly ranged from 57.9362 to 58.1187. Based on these 
data, a window of 58.01 ± 0.1 was selected to screen for peptide pairs in MALDI-TOF 
data set.  
Table 5.  Distribution of oberserved masses of two known α−amidated peptides 
and their precursors in MALDI-TOF data set. 
Low High Mean St. Dev. 
mJP 1941.0841 1941.1719 1941.13 0.04 
mJP-Gly 1999.0947 1999.1957 1999.14 0.04 
α-MSH 1622.9843 1623.0680 1623.04 0.03 
α-MSH-Gly 1681.0042 1681.1030 1681.06 0.04 
Data were based on at least 6 readings per peptide.  
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An example MS spectrum of mJP and mJP-Gly in LTQ-Orbitrap data set is shown in 
Figure 10, in which all peaks were shown in relative m/z to the monoisotopic peak of mJP. 
The observed mass difference between these two doubly charged peptides was 29.0025, 
very close to the theoretical value 29.0028. Shown in Table 6 is the distribution of 
observed masses of the four peptides in doubly charged state obtained by Orbitrap mass 
analyzer. Observed mass difference between doubly charged mJP and mJP-Gly ranged 
from 28.9960 to 29.0062 while that of α-MSH and α-MSH-Gly ranged from 28.9987 to 
29.0075. Based on these data, a window of 29.003 ± 0.01 was selected to screen for 
doubly charged peptide pairs in LTQ-Orbitrap data set. Screening windows for triply and 
singly charged peptide pairs were adjusted accordingly. 
Table 6.  Distribution of oberserved masses of two known amidated peptides 
and their precursors in LTQ-Orbitrap data set. 
 Low High Mean St. Dev. 
mJP 970.9301 970.9342 970.932 0.001 
mJP-Gly 999.9302 999.9363 999.934 0.001 
α-MSH 811.8932 811.8981 811.896 0.001 
α-MSH-Gly 840.8968 840.9007 840.899 0.001 
Data were based on 23 readings per peptide.  
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Figure 10.  Mass difference between mJP and mJP-Gly shown in a MS 
spectrum obtained by Orbitrap. 
Monoisotopic peak of mJP was set as zero. All other peaks were shown in relative 
masses. 
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2.3.1.4 Fragmentation pattern. 
MS/MS spectra of mJP and mJP-Gly are shown in Figure 11. These two peptides 
demonstrated very similar fragmentation pattern under CID. Corresponding b ions 
showed same mass value (marked with red arrows) while y ions showed a constant mass 
difference of 58 (marked with blue lines) resulting from the cleavage of C2H2O2 group 
from C-terminal of mJP-Gly by PAM. 
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Figure 11. MS/MS spectra of mouse joining peptide (mJP) and its 
glycine-extended precursor. 
Top: AEEEAVWGDGSPEPSPREG; bottom: AEEEAVWGDGSPEPSPRE-NH2.  
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2.3.2 LC-MALDI-TOF/TOF data set. 
2.3.2.1 α-Amidated peptide identified by database search. 
Database search yielded one α-amidated peptide as shown in Table 7. This peptide is 
the C-terminus of chromogranin A (CgA) following a dibasic (Arg-Arg) processing site.  
Table 7.  An α-amidated peptide identified by database search from 
LC-MALDI data set. 
 
Observed Mr(expt) Mr(calc) Delta Score Expect Peptide 
3176.24 3175.23 3174.66 0.57 67 0.005 R.AEDQELESLSAIEAELEKV 
AHQLQALRR.G+Amide(C-term) 
2.3.2.2 α-Amidated peptides identified by pair finding method. 
Surprisingly, two known α−amidated peptides were not reported by database search. 
The peak list was exported using Data Explorer (version 4.0, ABI, Foster City, CA, USA) 
and screened for peptide pairs as described previously. Based on the observed mass 
distribution data of two known α-amidated peptides and their glycine-extended 
precursors, a window of 58 ± 0.1 was applied to screen for peptide pairs. A list of over 
three hundred peptide pairs was obtained. An accumulation filter, defined as:  
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was used to filter out some of false positive pairs. Pairs containing signals with low S/N 
values were also filtered out since they were unlikely to yield decent MS/MS spectra.  
After these filters, the number of peptide pairs decreased to ~ 40. Manual inspection of the 
MS/MS spectra for these peptide pairs found 4 pairs with similar fragmentation patterns. 
After database search and manual interpretation, 3 of them were successfully interpreted, 
including the C-terminal fragment of CgA, mJP, and α-MSH (Table 8). 
Table 8.  α−Amidated peptides identified by pair finding method from 
LC-MALDI data set. 
 
Amidated Gly-extended  Sequence 
m/z intensity m/z intensity 
 
3176.2612 7614.902 3234.247 16972.81 (R)AEDQELESLSAIEAELEKVAHQLQALRr(G) 
1941.0909 1334.641 1999.111 6632.418 (R)AEEEAVWGDGSPEPSPRe(G) 
1622.9706 509.2811 1681.006 9935.948 (R)SYSMEHFRWGKPv(G) 
 
1
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
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
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
 −
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

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
 −
Control
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amidatedof
extendedGlyof
amidatedof
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2.3.3 LC-LTQ–Orbitrap data set 
2.3.3.1 α-Amidated peptides identified by database search. 
Over 15,000 MS/MS spectra were obtained from each LC-LTQ-Orbitrap experiment. 
Nine α−amidated peptides were identified through Sequest and Mascot database search 
(Table 9). Two sequences received very low probability due to poor spectrum quality. 
Table 9.  α−Amidated peptides identified by database search from LC-Orbitrap 
data set. 
Sequence Probability Modifications Observed 
Mass 
Actual 
Mass 
Delta 
AMU 
(R)AEEEAVWGDGSPEPSPRe(G) 95% Amide  970.9332 1939.85 -0.004 
(A)EEEAVWGDGSPEPSPRe(G) 95% Amide  935.4121 1868.81 -0.009 
(E)EEAVWGDGSPEPSPRe(G) 95% Amide  870.8919 1739.77 -0.007 
(E)EAVWGDGSPEPSPRe(G) 95% Amide 806.3709 1610.73 -0.007 
(E)AVWGDGSPEPSPRe(G) 3% Amide 741.8508 1481.69 -0.004 
(A)VWGDGSPEPSPRe(G) 95% Amide 706.3317 1410.65 -0.005 
(A)WGDGSPEPSPRe(G) 95% Amide 656.7975 1311.58 -0.000 
(G)DGSPEPSPRe(G) 2% Amide 535.2485 1068.48 -0.002 
(R)SYSMEHFRWGKPv(G) 95% Amide 811.8972 1621.78 -0.004 
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2.3.3.2 α-Amidated peptides identified by pair finding method. 
The peptide list was screened for peptide pairs with 58.006 ± 0.01 mass difference 
and similar retention time (within 2 minutes). A list of 33 pairs was obtained.  
Table 10.  Peptide pairs reported by pair finding method from LC-Orbitrap 
data set. 
  Obs. m/z of  
amidated 
Obs. m/z of  
Gly-ext. 
Charge 
state 
Mass 
difference 
R.T. 
difference 
Found by 
database 
search 
1 970.9304 999.9359 2 58.0110 -0.01 YES 
2 935.4109 964.4114 2 58.0010 0.08 YES 
3 871.8935 899.8951 2 58.0032 0.72 YES 
4 806.3690 835.3716 2 58.0052 1.22 YES 
5 741.8502 770.8514 2 58.0024 1.22 YES 
6 706.3295 735.3329 2 58.0068 1.67 YES 
7 656.8019 685.8043 2 58.0048 1.10 YES 
8 563.7588 592.7625 2 58.0074 1.22 NO 
9 535.2484 564.2518 2 58.0068 1.57 YES 
10 477.7352 506.7379 2 58.0054 1.09 NO 
11 811.8932 840.8983 2 58.0102 1.12 YES 
12 541.5995 560.9345 3 58.0050 0.50 YES 
13 471.2552 500.2572 2 58.0040 1.42 NO 
 67 
 
After manual inspection of these MS/MS spectra for this set of peptides, 13 pairs of 
peptides were found (Table 10) followed the fragmentation pattern of amidated peptides 
and precursors, including 9 amidated peptides reported by database search, triply charged 
α-MSH and 3 more interesting pairs (pair No. 8, 10, and 13). 
Shown in Figure 12 are MS/MS spectra for peptide pair No. 10. By looking for peaks 
with mass difference of 58 in two spectra, 4 pairs of y ion with m/z value 458.44 and 
400.30, 642.41 and 584.40, 771.46 and 713.23, and 868.66 and 810.51 were identified.  
These y ions are identical to y4, y6, y7 and y8 ions in the mJP peptide pair (Figure 11), 
suggesting this pair of peptides are also mJP related peptides. Based on the size of parent 
ions, the sequences were likely to be GSPEPSPREG and GSPEPSPRE-NH2. Although 
the complete sequences could not be deduced from the fragments, accurate mass 
measurements (-0.0013 (2.56 ppm) for GSPEPSPREG and -0.0009 (1.88 ppm) for 
GSPEPSPRE-NH2) as well as assigned b ions indicated that these were the correct 
sequences. Similarly, another pair of peptides was identified as GDGSPEPSPREG and 
GDGSPEPSPRE-NH2 (Figure 13).  
 68 
 
 
Figure 12.  Identification of peptide pair No. 10. 
Top: MS/MS spectrum of GSPEPSPREG; Bottom: MS/MS spectrum of 
GSPEPSPRE-NH2. Two spectra have y ions with 58 mass difference marked with blue 
lines, and b ions with same m/z value marked with red arrows. 
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Figure 13.  Identification of peptide pair No. 8. 
Top: MS/MS spectrum of GDGSPEPSPREG; Bottom: MS/MS spectrum of 
GDGSPEPSPRE-NH2. Two spectra have y ions with 58 mass difference marked with 
blue lines, and b ions with same m/z value marked with red arrows. 
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Spectra of the peptide pair No. 13 were shown in Figure 14. Peaks in two spectra with 
same m/z value (tentative b ions) were marked with red arrows.  Peaks with 58 mass 
difference (tentative y ions) were marked with blue lines. Through these peaks, partial 
sequence of this peptide was deduced to be EWR or EGER (Table 11). There was a 
constant difference of 18 between parent ion mass and the addition of tentative b ions and 
their corresponding y ions. For example, the addition of a tentative b ion 225.04 and its 
corresponding y ion 757.53 is 982.57 (with 2 positive charges), 18 less than observed 
parent ion mass 1000.51 (with 2 positive charges). This indicated water loss in either b 
ions or y ions. Fragment ions with +18 amu were found for 4 out of 5 tentative b ions 
while only 1 out 5 were found for tentative y ions, suggesting that water lose was from an 
amino acid residue at or close to N-terminus and that marked b ions in Figure 14 were 
actually b-H2O ions. With that in mind, fragment ions 243.05 and 286.31 were used to 
deduce the rest sequences at N-terminus and C-terminus, which turned out to be (L/I E) 
or (Q/K N) for N- and (L/I P )G for C-terminus. 
Table 11.  Fragment ions assignment for spectra of peptide pair No. 13. 
b-18 b Amino acid residues y 
225.04 243.05 (L/I E) or (Q/K N) 
353.99 372.24 E 757.53 
410.92 G 
W 
628.45 
540.04 558.35 E 571.39 
696.43 714.43 R 442.41 
(L/I P )G 286.31 
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Figure 14.  Spectra of peptide pair No. 13. 
Spectral pair found by the pair finding method. Two spectra have peaks with 58 mass 
difference (tentative y ions, marked with blue lines) and peaks with same m/z value 
(tentative b ions, marked with red arrows). 
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All possible sequences for the tentative glycine-extended peptide in pair No. 13 are 
shown in Table 12, together with corresponding delta m/z and ppm values. Considering 
the mass measurement accuracy of Orbitrap mass analyzer, the actual sequence of this 
peptide is most likely to be (QN)EWR(L/I P)G or (L/I E)EGER(L/I P)G. All 24 
permutations for these two combinations were searched against mouse non-redundant 
protein sequences (NR) database using Basic Local Alignment Search Tool (BLAST) 
(Parameters: blastp, expect=20000, PAM30, word size 2). Exact match was found for 
sequence ELEGERPLG. A BLAST search against mouse translated nucleotide database 
(Parameters: tblastn, expect=100000, no filter, PAM30, word size 2) yielded one exact 
match for sequence QNEWRIPG. 
Table 12.  Possible sequences for the tentative glycine-extended peptide in pair 
No. 13. 
Sequence delta m/z ppm 
(Q N) EWR(L/I P)G 0.0032 6.3967 
(L/I E)EWR(L/I P)G -0.0093 -18.5904 
(K N) EWR(L/I P)G -0.0150 -29.9846 
(L/I E) EGER(L/I P)G -0.0020 -3.9979 
(K N) EGER(L/I P)G -0.0073 -14.5925 
(Q N) EGER(L/I P)G 0.0109 21.7888 
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Peptides QNEWRIPG and ELEGERPL-NH2 were synthesized and subjected to 
LC-ESI-LTQ-Orbitrap analysis. Retention time of the two synthetic peptides and the 
unknown are shown in XICs in Figure 15. Peptide ELEGERPL-NH2 showed a similar 
retention time to that of the unknown. The MS/MS spectrum of peptide ELEGERPL-NH2 
as shown in Figure 16 almost exactly matched that of the unknown (the bottom spectrum 
in Figure 14). Therefore, the peptide sequences in this pair were confirmed as 
ELEGERPLG and ELEGERPL-NH2.  
 
 
Figure 15.  XICs showing retention time of two synthetic peptides and the 
unknown. 
The unknown refers to the peptide with m/z value 471.2552 in pair No. 13, a tentative 
α-amidated peptide.  
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Figure 16.  MS/MS spectra of synthetic pepitdes QNEWRIPG and 
ELEGERPL-NH2 . 
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In summary, a total of 13 peptide pairs were identified using pair finding method as 
listed in Table 13. Twelve of the 13 α-amidated peptides were identified in AtT-20 cells, 
including all 9 peptides reported by database search and 3 additional. 
Table 13.  α−Amidated peptides identified by pair finding method from 
LC-Orbitrap data set. 
  Obs. m/z  Charge state Sequence 
1 970.9304 2 (R)AEEEAVWGDGSPEPSPRe(G) 
2 935.4109 2 (A)EEEAVWGDGSPEPSPRe(G) 
3 871.8935 2 (E)EEAVWGDGSPEPSPRe(G) 
4 806.3690 2 (E)EAVWGDGSPEPSPRe(G) 
5 741.8502 2 (E)AVWGDGSPEPSPRe(G) 
6 706.3295 2 (A)VWGDGSPEPSPRe(G) 
7 656.8019 2 (V) WGDGSPEPSPRe(G) 
8 563.7588 2 (W)GDGSPEPSPRe(G) 
9 535.2484 2 (G)DGSPEPSPRe(G) 
10 477.7352 2 (D)GSPEPSPRe(G) 
11 811.8932 2 (R)SYSMEHFRWGKPv(G) 
12 541.5995 3 (R)SYSMEHFRWGKPv(G) 
13 471.2552 2 (R)ELEGERPl(G) 
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2.3.4 Complementary peptide extraction methods. 
Acidic solvents are commonly used to extract endogenous peptides from biological 
sources.  Properly designed acidic extraction solution can minimize protease activity 
and increase solubilization of peptides (Bennett et al. 1981). Acidic extraction is often 
used in combination with heating or boiling to liberate peptides (Conlon 2007, Nylander 
et al. 1997). However, it has been suggested that the hot acidic extraction conditions may 
result in protein or peptide degradation, the products of which will obscure endogenous 
peptide identification (Che et al. 2007). To limit possible degradations, acidic extractions 
in this study were all carried out at 4 ºC. 
Urea (8 M) was also used as a complementary extraction solvent to produce a more 
comprehensive and less biased total endogenous peptide extract. Urea in aqueous solution 
will form ammonium cyanate through isomeric transformation over time. The 
isomerization is spontaneous at high temperature and very slow at low temperature 
(Dirnhuber and Schutz 1948). Cyanate is highly reactive and will readily, nonspecifically, 
and irreversibly carbamylate free amine groups. To avoid this unwanted modification of 
endogenous peptides, the urea solution was prepared freshly just before use and peptide 
extraction was carried out at 4 ºC.  
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Table 14.  Comparison of identified α-amidated peptides using two extraction 
solutions. 
Obs. m/z  Charge state Sequence Acid ex. Urea ex. 
970.9304 2 (R)AEEEAVWGDGSPEPSPRe(G) Yes Yes 
935.4109 2 (A)EEEAVWGDGSPEPSPRe(G) Yes Yes 
871.8935 2 (E)EEAVWGDGSPEPSPRe(G) Yes Yes 
806.3690 2 (E)EAVWGDGSPEPSPRe(G) Yes Yes 
741.8502 2 (E)AVWGDGSPEPSPRe(G) Yes Yes 
706.3295 2 (A)VWGDGSPEPSPRe(G) Yes Yes 
656.8019 2 (V) WGDGSPEPSPRe(G) Yes Yes 
563.7588 2 (W)GDGSPEPSPRe(G) No Yes 
535.2484 2 (G)DGSPEPSPRe(G) Yes No 
477.7352 2 (D)GSPEPSPRe(G) Yes No 
811.8932 2 (R)SYSMEHFRWGKPv(G) Yes Yes 
541.5995 3 (R)SYSMEHFRWGKPv(G) Yes Yes 
471.2552 2 (R)ELEGERPl(G) Yes Yes 
Acid extract solution contains 0.1M HCl, 5% (v/v) formic acid, 1% (w/v) NaCl and 1% 
(v/v) TFA (Bennett et al. 1981). The 8 M urea solution was prepared fresh before use. All 
extractions were carried out at 4 ºC to minimize degradation and unwanted reactions. 
Shown in Table 14 are the α-amidatedpeptides identified using two solvent systems. 
Most of the peptides were found in both extracts. However, the two extraction systems do 
show complementary results for less abundant peptides:  GDGSPEPSPRE-NH2 was 
found in urea extract only while DGSPEPSPRE-NH2 and GSPEPSPRE-NH2 were only 
found in the acidic extract.  
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2.4 Discussion 
2.4.1 Identification of endogenous peptides with PTM. 
2.4.1.1 Limits of modern database search based endogenous peptide identification. 
Liquid chromatography (LC) coupled with tandem mass spectrometry (MS/MS) has 
emerged as a powerful tool for the identification of endogenous peptides from biological 
samples. The standard MS/MS data processing procedure is using MASCOT, SEQUEST 
or other database search engine(s) to compare theoretical spectra generated from database 
sequences with those obtained experimentally. Despite of the success this approach (as 
demonstrated in this thesis), problems remain.  Endogenous peptides are usually 
produced from their precursors by a series of chemical modifications catalyzed by 
different enzymes (Steiner 1998). The specificity for some of the enzymes is currently 
unknown. Consequently, processing sites of endogenous peptides are variable. Therefore, 
“no enzyme” has to be used when generating the theoretical spectra from database 
sequences, which means all possible subsequences of each protein have to be tested. For 
a protein of N amino acid residues, there are N(N+1)/2 subsequences. Moreover, most 
endogenous peptides undergo extensive PTMs such as C-terminal amidation, 
phosphorylation, acetylation and sulfation (Hummon et al. 2006). Operators can specify 
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some expected PTMs as “variable modifications” in most database search engines before 
the search. However, database searches take much longer when multiple variable PTMs 
are chosen because the program has to consider all peptide sequences without PTMs and 
with PTMs of different combinations. If M variable PTMs are selected, 2MN(N+1)/2 
subsequences must be tested for a protein of N amino acid residues. Considering the fact 
that a modern LC-MS/MS instrument generates tens of thousands MS/MS spectra per 
hour, database searching takes much longer than collecting the spectra and, thus, 
becomes a bottleneck for endogenous peptide identification. To alleviate this problem, a 
database specially designed for endogenous peptide identification, SwePep, was 
constructed (Falth et al. 2006, Falth et al. 2008) which contains known endogenous 
peptides from different species. To use this database, the masses of experimental peptides 
will be compared with masses of peptides stored in the database. The identities of 
matched peptides are then verified by comparing experimental MS/MS spectra with 
stored spectra. Searching against this database for endogenous peptides can be 
dramatically increased in contrast to conventional databases. However, this method is 
good for re-identification of known peptides only and cannot be used for discovery of 
novel peptides, which are probably not present in the database.  
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The other problem with database search based peptide identification is the low 
identification rate. Only 5% to 10% of the MS/MS spectra can be correctly interpreted in 
a typical LC-MS/MS assay (Keller et al. 2002). A majority of the MS/MS spectra receive 
a low score due to unknown modifications (Ye et al. 2010, Savitski et al. 2006), poor 
spectrum quality, (Mujezinovic et al. 2010), and/or mixture spectra (Chen, Drogaris and 
Bern 2010). On the other hand, a significant number of sequence assignments with high 
scores are false positives due to misinterpretation of PTMs, incorrect assignment of PTM 
sites, and incorrect use of isotopic peaks (Chen 2008). False positives due to misuse of 
isotopic peaks is especially substantial for α-amidated peptide identification. The mass of 
an α-amidated peptide is 0.984 Da smaller than its unmodified form (note: the one with 
exact sequence but free C-terminal carboxyl group, not glycine-extended precursor), very 
close to 1.008 Da which is the mass difference between isotopic peaks. If a higher 
isotopic peak of an α-amidated peptide was chosen for MS/MS instead of the 
monoisotopic peak, which is often seen in many cases, the search engine will very likely 
identify the peptide as a peptide with free C-terminus instead of C-terminal amide. 
Shown in Figure 17 is an example of misinterpretation of an α-amidated peptide by 
database search resulting from the misuse of isotopic peaks. For a small dataset, manual 
interpretation is likely to identify more peptides of interest. However, manual 
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interpretation of large data sets containing thousands of spectra is unfeasible for the high 
throughput identification of potential α-amidated peptides. 
 
Figure 17.  A false positive peptide identification by database search due to 
misuse of isotopic peaks. 
A: Assignment of an MS/MS spectrum with a doubly charged peptide 
VWGDGSPEPSPRE identified by Sequest with a probability of 95%. B: Delta mass 
errors of fragment ions with high error values for y ions due to misinterpretation of 
α−amidated C-terminus with free C-terminus. C: Isotopic distribution of the parent 
peptide. The second isotopic peak m/z 706.83 was used as parent ion instead of the 
monoisotopic peak m/z 706.33. As a result, the α-amidated peptide 
VWGDGSPEPSPRE-NH2 was misinterpreted as an unmodified peptide 
VWGDGSPEPSPRE with a probability of 95%.  
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2.4.1.2 Peptide-pair strategy, the solution to the screening of endogenous 
α-amidated peptides. 
Screening a large data set of LC-MS/MS spectra for putative α-amidated peptides can 
be accomplished using the peptide-pair strategy presented in this study. The essence of 
our peptide-pair strategy is to greatly reduce the number of spectra requiring 
interpretation. From the 15,580 MS/MS spectra obtained from the LTQ-Orbitrap 
experiment, the pair screening method yielded 33 pairs of interesting spectra, a decrease 
in computing time of 99.6% for the database search. The significant reduction in number 
of spectra to be interpreted made manual interpretation possible leading to the 
identification of novel α-amidated peptides. In this study, three more amidated peptides 
were identified through manual interpretation. 
A few tools and methods have been developed to detect general peptide/protein PTMs 
based on spectral pair finding strategy, such as ModifiComb (Savitski et al. 2006), Mass 
Distance Fingerprint (Potthast et al. 2007), and more (Bandeira et al. 2006, Fu et al. 
2009). These methods were designed for detection of general PTMs without prior 
assumption of their chemical composition and attachment sites, making them especially 
useful to detect and characterize novel or unexpected PTMs. However, these methods 
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only detect predominant and abundant modifications, because spectra of modified and 
unmodified peptides need to show up repeatedly to be found. Also, these methods work 
under the assumption that both modified and unmodified peptides are present in the 
sample, which is not necessarily true in the experimental samples, especially for 
irreversible PTMs. Different from these approaches, the method presented in this thesis 
was designed to screen for peptides with known modification, based on a well-defined 
biosynthetic pathway. By combining the peptides from both a PAM inhibited sample and 
the control sample, the coexistence of modified peptides and their precursors were 
guaranteed. Furthermore, since the mass difference was specified when scanning for 
peptide pairs, this method is sufficiently sensitive to identify peptides that only have one 
spectrum, like the novel α-amidated peptide ELEGERPL-NH2 identified in 
LTQ-Orbitrap dataset.   
2.4.2 Mass measurement accuracy and false positives. 
Mass measurement accuracy plays a key role in this peptide-pair screening method. 
When MALDI-TOF/TOF and external calibration were used, a wide window of ± 0.1 Da 
was required to screen for peptide pairs due to the relatively low mass measurement 
accuracy (Table 5). This screening window yielded a list of over 300 peptide pairs, most 
of which were false positives. To remove these false positives, samples from PAM 
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inhibited group and control group had to be analyzed separately to obtain peptide 
intensities in two groups. With this information, an accumulation filter was applied to 
remove peptides which did not accumulate in PAM inhibitor treated group. 
For LC-MS/MS, Orbitrap is a very accurate mass analyzer; experimental trials using 
digested BSA between each assay showed errors in the measurement of mass of less than 
3 ppm. Consequently, a window significantly smaller was used to screen for peptide pairs. 
This narrow window successfully decreased false positive rate to an acceptable level and 
made the accumulation filter unnecessary. Therefore, peptide samples from two groups 
could be combined and processed together to decrease the effort by half. 
With the help of high mass measurement accuracy and accumulation information, 
false positive rate was confined to a relatively low level using mass difference and 
retention time as screening conditions. The third restriction, the MS/MS spectra similarity 
check, eliminated most false positives. However, in some rare cases, two peptides might 
have very similar sequences and only differ from each other by a few residues. If the 
mass difference between the distinct parts in two peptides happened to correspond closely 
to 58.005, the two peptides would meet all three screening conditions and, therefore, 
would result in a false positive. An extreme situation is two peptides with identical 
sequences except one having GVT as C-terminus and the other one having KA as 
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C-terminus. In this case, the two peptides would show similar retention times and would 
have a mass difference of 58.0055, exactly matches the difference between an 
α-amidated peptide and its glycine-extended precursor. Moreover, since the N-terminal 
sequences of the two peptide are the same, they would generate MS/MS spectra that 
appear like an α-amidated peptide and its glycine-extended precursor, i.e. MS/MS spectra 
with same fragment ions and ions with a 58 mass difference. 
Shown in Figure 18 are the MS/MS spectra of a false positive pair found in peptide 
extract from the AtT-20 cells. The two triply charged peptides demonstrated an observed 
mass difference of 19.3385 which is in the range of an α-amidated peptide and its 
glycine-extended precursor. They also showed similar retention times with a difference of 
only 1.2 minutes.  At least 7 related ion pairs (with same mass or with 58 mass 
difference) in MS/MS spectra were found as marked in Figure 18. However, sequences 
for these two peptides turned out to be PEPSRSTPAPKKGSKK (Figure 41) and 
PEPSKSAPAPKKGSKK (Figure 42). The two peptides have very similar sequences 
except two residues: R, T in one and K, A in the other. Mass difference between the two 
combinations happens to be 58 amu. 
Although this situation happens infrequently, it must be considered when spectra of a 
peptide pair could not be interpreted with the assumption one being α-amidated peptide 
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and the other being its glycine-extended precursor. To check if a peptide pair is a false 
positive, one can compare the relative concentration of the two peptides in samples from 
PAM inhibited and control group to see if there is any significant difference. The other 
option is to incubate the sample with PAM to see if the relative amount of the larger 
peptide decreases. The relative concentrations of two peptides in a false positive pair 
would not show any relation to PAM activities.  
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Figure 18.  MS/MS spectra for a false positive peptide pair. 
The two sequences were identified to be PEPSRSTPAPKKGSKK (Figure 41) and 
PEPSKSAPAPKKGSKK (Figure 42). 
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2.4.3 α-Amidated peptides identified. 
2.4.3.1 Mouse joining peptide related peptides. 
Joining peptide is one of the peptides generated from prohormone 
pro-opiomelanocortin (POMC), which is abundant in pituitary, gut, adrenal gland, and 
bronchial carcinoids (Bjartell et al. 1990, Cullen and Mains 1987, Fenger 1991). Most 
peptides derived from POMC are hormones, such as corticotropin, melanotropin, 
lipotropin, and endorphin (Table 15). Although mouse joining peptide has the typical 
characteristics of peptide hormones, i.e. C-terminal amidation and flanked with dibasic 
processing sites, it is the only POMC-derived peptide without a conclusive bioactivity.  
In UniProtKB/Swiss-Prot database, this peptide is denoted as a “propeptide”. 
 Efforts have been made to identify the function of joining peptide. In 1992, bovine 
joining peptide was found to weakly inhibit the sodium pump (IC50 = 0.5mM) 
(Hamakubo et al. 1992). Dose dependent central cardiovascular effects of this peptide 
were later observed on genetically hypertensive rats (Hamakubo et al. 1993). In 1994, rat 
joining peptide was also reported with central cardiovascular effects and these effects 
were mediated by angiotensin II (Yoshida, Hamakubo and Inagami 1994). However, 
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none of these reported activities for joining peptide have been corroborated by other 
researchers.  
Table 15.  Peptide hormones derived from POMC (mouse). 
Position Length Description 
1 – 26 26 Signal peptide 
27 – 100 74 NPP 
77 – 87 11 Melanotropin gamma 
103 – 121 19 Propeptide (Joining peptide) 
124 – 162 39 Corticotropin 
124 – 136 13 Melanotropin alpha 
142 – 162 21 Corticotropin-like intermediary peptide 
165 – 235 71 Lipotropin beta 
165 – 202 38 Lipotropin gamma 
185 – 202 18 Melanotropin beta 
205 – 235 31 Beta-endorphin 
205 – 209 5 Met-enkephalin 
 
As reported in this thesis, a series of mouse joining peptide related peptides with 
sequential N-terminal deletions were identified in mouse pituitary AtT-20 cells (Table 
13). This suggests that mouse joining peptide is a prohormone and, thus, may not, in 
itself, have significant bioactivity. One or more of the mJP-derived C-terminal fragments 
could serve as bioactive peptide hormones. To test this hypothesis, mJP, mJP-Gly and 
one of mJP C-terminal fragments GDGSPEPSPRE-NH2 (mJP-F7) were synthesized and 
their inhibition activities on porcine Na/K-ATPase were examined. As shown in Figure 
19, the glycine extended precursor mJP-Gly showed little inhibition of the ATPase. In 
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contrast, while mature, α-amidated mJP showed about 20% inhibition, which hinted a 
key role of C-terminal amide for this inhibition activity. Moreover, the fragment peptide 
mJP-F7 demonstrated stronger inhibition activity than mJP. This suggested N-terminal 
deletion of mJP may lead to a peptide of greater bioactivity.  
 
 
Figure 19.  Inhibition effects of three mJP related peptides on Na/K ATPase. 
Experiments were performed as indicated in the Material and Method section with the 
presence of 0.46 mM of the peptide to be investigated. The enzyme activities were 
converted to relative activities to the control reaction, i.e. reactions with no peptides 
presented.  
Rat joining peptide was reported to be able to increase blood pressure and heart rate by 
increasing the level of angiotensin (ANG) II (Yoshida et al. 1994). ANG II is the most 
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active form of the angiotensins which is converted from inactive ANG I (DRVYIHPFHL) 
by removal of two C-terminal residues, a reaction catalyzed by angiotensin converting 
enzyme (ACE). Activation effects of mJP on ACE were tested with two different 
concentrations as shown in Figure 20.  mJP at 175 µM showed no significant effect on 
ACE activity while 350 µM mJP inhibited ACS slightly, 2.9 %. These data suggest that the 
up-regulation of ANG II by mJP is not through ACE activation. Another possible 
mechanism is that the inhibition of sodium pump by mJP decreases the plasma sodium 
level which in turn activates renin secretion (Barrett et al. 1989). Renin is the enzyme 
which catalyzes the cleavage of angiotensinogen to produce ANG I. Increased renin levels 
would produce more ANG I and, thus, more ANG II. 
Further screening studies on mJP and its C-terminal fragments are required to validate 
the biofunction of this abundant and yet uncharacterized endogenous peptide.  
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Figure 20.  Effects of mJP on ACE activity. 
Experiments were performed as indicated in the Material and Method section with the 
presence of mJP. The enzyme activities were converted to relative activities to the control 
reaction, i.e. reactions with no mJP presented.  
2.4.3.2 β-Lipotropin related peptide. 
β-Lipotropin (β-LPH) is another peptide hormone derived from POMC. β-LPH 
performs lipid-mobilizing functions (Keda Yu and Pankov Yu 1987, Richter, Jacob and 
Schwandt 1990) and stimulates adrenal steroid production (Oconnell, McKenna and 
Cunningham 1996, Oconnell, McKenna and Cunningham 1993). It was also found to be 
correlated with severity of postoperative pain (Matejec et al. 2006a, Matejec et al. 2006b). 
Shown in Figure 21 is the sequence of mouse POMC 165-235 fragment with β-LPH 
being marked with the underscore.  The N-terminal fragment of β-LPH 165-202, 
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marked with bold font, is another peptide hormone γ-lipotropin. An even shorter 
N-terminal fragment 165-172, marked with red bold font, was discovered in both mouse 
pituitary tumor cell line and mouse pituitary tissue with C-terminal amidation which is 
highly suggestive of biological function. This α-amidated endogenous peptide has never 
been reported. 
MPRFCYSRSG ALLLALLLQT SIDVWSWCLE SSQCQDLTTE SNLLACIRAC KLDLSLETPV  
FPGNGDEQPL TENPRKYVMG HFRWDRFGPR NSSSAGSAAQ RRAEEEAVWG DGSPEPSPRE  
GKRSYSMEHF RWGKPVGKKR RPVKVYPNVA ENESAEAFPL EFKRELEGER PLGLEQVLES  
DAEKDDGPYR VEHFRWSNPP KDKRYGGFMT SEKSQTPLVT LFKNAIIKNA HKKGQ  
Figure 21.  Sequence of mouse pro-opiomelanocortin. 
Fragment 165-235( marked with underlined text) is β-lipotropin. Fragment 165-202 
(marked with bold font) γ-lipotropin. Fragment 165-172 (marked with red bold font) is a 
novel α-amidated peptide discovered in both mouse pituitary tumor cell line and mouse 
pituitary tissue. 
 
2.4.3.3 Chromogranin A related peptide. 
Chromogranin A (CgA) is an acidic protein with widespread distribution in secretory 
cells of the nervous, endocrine and immune system. It has been suggested that one 
function of this protein is to serve as a prohormone for many bioactive peptides including 
vasostatins, chromofungin, pancreastatin, catestatin and parastatin (Helle et al. 2007, 
Iacangelo and Eiden 1995). The amidated C-terminal fragment of this protein was first 
found in 2006 in a rat insulinoma cell line Rin-m5F (Taylor et al. 2006). The same 
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peptide was identified in mouse AtT-20 cells, as reported here (Table 7). Similar 
α-amidated peptides GR-44 and ER-37 were also found in a human insulinoma tumor 
extract (Orr et al. 1998, Orr et al. 2002). The C-terminal domain of CgA containing these 
α-amidated peptides is highly conserved between vertebrate species (Figure 22C). The 
high degree conservation, basic cleavage sites flanking these peptides, and the presence 
of C-terminal amidation suggests that these peptides have undiscovered biological 
functions. 
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A: 
Rat Chromogranin A: 
MRSSAALALL LCAGQVFALP VNSPMTKGDT KVMKCVLEVI SDSLSKPSPM PVSPECLETL  
QGDERVLSIL RHQNLLKELQ DLALQGAKER AQQQQQQQQQ QQQQQQQQQQ QHSSFEDELS  
EVFENQSPAA KHGDAASEAP SKDTVEKRED SDKGQQDAFE GTTEGPRPQA FPEPKQESSM  
MGNSQSPGED TANNTQSPTS LPSQEHGIPQ TTEGSERGPS AQQQARKAKQ EEKEEEEEEK  
EEEEEEKEEK AIAREKAGPK EVPTAASSSH FYSGYKKIQK DDDGQSESQA VNGKTGASEA  
VPSEGKGELE HSQQEEDGEE AMAGPPQGLF PGGKGQELER KQQEEEEEEE RLSREWEDKR  
WSRMDQLAKE LTAEKRLEGE DDPDRSMKLS FRARAYGFRD PGPQLRRGWR PSSREDSVEA  
RGDFEEKKEE EGSANRRAED QELESLSAIE AELEKVAHQL QALRRG  
 
B: 
Human Chromogranin A 
MRSAAVLALL LCAGQVTALP VNSPMNKGDT EVMKCIVEVI SDTLSKPSPM PVSQECFETL  
RGDERILSIL RHQNLLKELQ DLALQGAKER AHQQKKHSGF EDELSEVLEN QSSQAELKEA  
VEEPSSKDVM EKREDSKEAE KSGEATDGAR PQALPEPMQE SKAEGNNQAP GEEEEEEEEA  
TNTHPPASLP SQKYPGPQAE GDSEGLSQGL VDREKGLSAE PGWQAKREEE EEEEEEAEAG  
EEAVPEEEGP TVVLNPHPSL GYKEIRKGES RSEALAVDGA GKPGAEEAQD PEGKGEQEHS  
QQKEEEEEMA VVPQGLFRGG KSGELEQEEE RLSKEWEDSK RWSKMDQLAK ELTAEKRLEG  
QEEEEDNRDS SMKLSFRARA YGFRGPGPQL RRGWRPSSRE DSLEAGLPLQ VRGYPEEKKE  
EEGSANRRPE DQELESLSAI EAELEKVAHQ LQALRRG  
 
C: 
…RGYPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLEELRRG  bovine 
…RGYPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRRG  human 
…RXYLEEKKEEEGSANRRPEDQELESLSAIEAELEKVAPQLQSLRRG  pig 
…RGDFEEKKEEEGSANRRAEDQELESLSAIEAELEKVAHQLQALRRG  rat 
…RSDFEEKKEEEGSANRRAEDQELESLSAIEAELEKVAHQLQALRRG  mouse 
…RGYPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRRG  horse 
Figure 22.  Sequences of chromogranin A of several spieces. 
A: sequence of rat chromogranin A (CgA) with the identified α-amidated peptide marked 
in red. 
B: sequence of human CgA with the identified α-amidated peptide marked in red. 
C: High degree conservation of CgA C-terminal region between vertebrate species. 
 96 
 
2.5 Concluding remarks 
A new strategy for the discovery and identification of α-amidated peptides is 
described in this chapter. This approach is based on the biosynthesis of peptide 
C-terminal amide and the high mass measurement accuracy. The coexistence of 
α-amidated peptides and their glycine-extended precursors was insured by the use of a 
PAM inhibitor. Peptides were scanned for pairs with mass difference of 58 Da and 
similar retention times. Interesting pairs were further validated by comparing their 
fragmentation patterns in MS/MS spectra. This method is able to significantly reduce 
workload of spectra interpretation and increase the identification rate of amidated 
peptides. Number of spectra to be interpreted was decreased from 15580 to 66 in 
LTQ-Orbitrap dataset. Three α-amidated peptides were identified in addition to 9 
peptides reported by database search from AtT-20 cell line (Table 13), representing a 
significant improvement in the detection of these modified sequences. 
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Chapter 3 Enrichment of α-Amidated Peptides 
3.1 Introduction 
3.1.1 PTM specific enrichment. 
Traditional PTM identification methods include Edman degradation, amino acid 
analysis, radioactive isotope labeling, and immunochemistry approaches (Zhao and 
Jensen 2009). These methods are laborious and incapable of handling complex samples. 
Within the past two decades, mass spectrometry coupled with liquid chromatography has 
proven powerful for the study of PTMs due to its high sensitivity and its ability to map 
PTM sites, to discover novel PTMs, to handle complex samples, and to quantify the 
changes of PTMs at distinct sites (Larsen et al. 2006). Typically, MS based PTM 
identification involves four steps: digestion, enrichment, LC-MS/MS assay, and 
verification (Zhao and Jensen 2009). Digestion can be done before (affinity enrichment) 
or after (covalent capture enrichment) the enrichment step. For endogenous PTM peptide 
studies, digestion may or may not be necessary based on the sizes of peptides of interest. 
PTM-specific protein/peptide enrichment is an essential step because most PTMs are in 
low abundance. Without enrichment procedures, mass spectrometric analysis of PTM 
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peptides shows low efficiency despite advances in the sensitivity of mass spectrometers 
and the development of database searching algorithms (Zhao and Jensen 2009). Current 
PTM-specific enrichment methods are (a) antibody-based affinity method, (b) ionic 
interaction-based, (c) enzyme-based, or (d) chemical derivatization-based. 
3.1.1.1 Antibody based affinity method. 
A few monoclonal antibodies have been developed to target a PTM-of-interest, 
independent of the specific protein possessing the modification. These antibodies can be 
used in global PTM analysis. Successful examples include antibodies directed against 
phosphotyrosine (Mann et al. 2002, Rush et al. 2005), phosphoserine/threonine 
(Gronborg et al. 2002), acetyllysine antibody (Kim et al. 2006), and nitrotyrosine (Zhan 
and Desiderio 2006). Antibodies for PTMs which introduce large changes to peptides are 
relatively easy to develop, especially for those occurring only on certain amino acid 
residue(s). For PTMs introducing small changes and without specific sites, for example 
C-terminal amidation, represent a difficult challenge for the development of antibodies 
for global PTM analysis.  
Lectins, sometimes referred to sugar-specific antibodies (Gabius et al. 2002), are 
carbohydrate binding proteins that recognize specific carbohydrate structures. 
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Lectin-based enrichment methods have been widely used in glycoprotein and 
glycopeptide studies (Budnik, Lee and Steen 2006, Dai et al. 2009).  
3.1.1.2 Ionic interaction-based affinity method 
Negatively charged phosphopeptides bind to immobilized metal ions such as Fe3+ and 
Ga3+, and can be eluted after the removal of non-specifically bound peptides. Utilizing 
this enrichment strategy, Ficarro et al. (Ficarro et al. 2002) identified over 1000 candidate 
phosphopeptides from S. cerevisiae whole cell lysate. Of these, 216 were manually 
validated and sites of phosphorylation were confirmed. This represents the most 
extensive list of confirmed phosphorylation sites determined to date. Taking advantage of 
charge differences between phosphopeptides and non-phosphopeptides, separation 
technologies such as strong anion exchange chromatography (SAX) and strong cation 
exchange chromatography (SCX) can be used prior to the enrichment procedure to 
prefractionate samples and decrease their complexity.  
3.1.1.3 Enzyme-based affinity method. 
Enzymes are attractive reagents to enrich PTM peptides due to their high specificity. 
Some enzymes can be deactivated by mutation of one or more amino acid residue(s) in 
active site, or by removal of metal ions without compromising ligand affinity or global 
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3-dimensional structure. Such deactivated enzymes can be immobilized and used to 
enrich their substrate peptides from a complex mixture.  
Trypsin is a protease which cleaves peptides at the C-terminal side of lysine (Lys) and 
arginine (Arg). Conversion of Ser-195 in the trypsin active site to dehydroalanine yields a 
catalytically inert derivative of trypsin, called anhydrotrypsin, which can still bind 
Lys/Arg containing peptide substrates (Ishii et al. 1983). As discussed in Chapter 1.1.2, 
endogenous peptides are synthesized as inactive prohormones and then cleaved by 
prohormone convertases (Table 2) usually on the C-terminal side of basic amino acid 
residues (Lys or Arg). Basic amino acid residues at C-termini of the peptides are then 
removed by carboxypeptidase E (CPE). Che et al. utilized Cpefat/Cpefat mice which 
produce mutated CPE to get accumulation of neuroendocrine peptides with C-terminal 
basic amino acid residues. These peptides were then enriched and isolated using an 
anhydrotrypsin affinity column.(Che et al. 2001) 
3.1.1.4 Chemical derivatization based method. 
Chemical approaches have been developed to attach an affinity linker to the PTMs. 
The affinity linker is used in the subsequent enrichment procedure. A good example is 
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introducing biotin to PTMs, which can be used to "tag" and isolate PTM peptides from a 
mixture using avidin conjugated beads.  
Tagging PTMs can be carried out chemically in vitro. In protein phosphorylation 
studies, the biotin tag can be introduced by β-elimination of phosphoric acid followed by 
Michael addition (Oda, Nagasu and Chait 2001, Goshe et al. 2001). Also with 
β-elimination and Michael addition, dithiothreitol (DTT) or biotin pentylamine was 
attached to sites modified by O-GlcNAc (Wells et al. 2002). A similar approach was 
applied to the study of S-nitrosylated proteins (Jaffrey et al. 2001), where incorporation 
of biotin to nitrosylated-cysteine serves both stabilization and enrichment purposes. 
While useful, in vitro chemical derivatization of PTM suffers from various drawbacks 
such as sample loss, inefficiencies in the chemical reaction, and unwanted side products. 
Thus, procedures with multiple reactions should be avoided to minimize sample losses. 
PTMs can also be tagged in vivo through metabolic labeling. In studies of 
S-glutathionylation, glutathione (GSH, the tripeptide, γGlu-Cys-Gly) (Huang et al. 2008, 
Velu et al. 2007), as well as its oxidized form glutathione disulfide (GSSG) (Brennan et 
al. 2006), and ethyl ester (Sullivan et al. 2000) can be easily biotinylated. Incubation of 
cell lines with these membrane permeable, biotinylated GSH-based modifiers under 
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oxidative stress induced their incorporation at S-glutathionylation sites. The biotin moiety 
of these modifiers was then used to enrich for S-glutathionylated proteins.   
3.1.2 α-Amidated peptide enrichment. 
No enrichment method specific to α-amidation has been reported thus far.  
Antibodies that can globally differentiate between peptides with C-terminal amide from 
peptides with a C-terminal carboxylate have never been successfully developed. 
Although it has been reported that the C-terminal amide can be converted to amine using 
the Hoffman rearrangement (Hill et al. 1993), which could be used as chemical 
derivatization site for tagging and enrichment purposes, preliminary studies were 
unsuccessful due to many side reactions on peptide side chains (data not shown).  
PHM is a copper dependent enzyme that catalyzes the first step of two-step peptide 
amidation reaction. Removal of the copper ions results in the loss of enzyme catalytic 
activity (Bell et al. 1997). Therefore, when incubating copper depleted PHM (apo-PHM) 
with a peptide mixture, glycine-extended peptide substrates should bind and remain 
enzyme-bound until activity is restored by addition of copper. All peptides that are not 
bound to apo-PHM could be removed using separation techniques like ultrafiltration or 
size exclusion filtration. Thus, apo-PHM could emerge as a powerful tool to enrich for 
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α-amidated peptide precursors. This chapter shows enrichment experiments on several 
synthetic model peptides. Peptide extracts from cells grown in the presence of PHM 
inhibitor to accumulated glycine-extended precursors peptides were be used to test the 
ability of the newly developed enrichment method to handle complex samples. 
3.2 Material and Methods 
3.2.1 Materials. 
Apo-PHM (rat PHMcc residues 42–356 expressed in CHO DG44 cell line) was a 
generous gift from Dr. N. J. Blackburn (Department of Biochemistry and Molecular 
Biology, OGI School of Science and Engineering, Oregon Health and Science University, 
OR, USA).  Dansyl-Ala-Arg, Ac-RFMWMK-NH2 and ELPLQNFWLCFR-NH2 were 
from Bachem (King of Prussia, PA, USA). Dansyl-Tyr-Val-Gly and disulfiram were 
from Fluka. The mouse pituitary AtT-20 cell line and basal F-12K medium (Kaighn's 
Modification of Ham's F-12 Medium) were purchased from American Type Culture 
Collection. Fetal bovine serum was from Atlanta Biologicals. Donor equine serum was 
from Thermo Scientific. CHCA (α-cyano-4-hydroxycinnamic acid) was from 
Sigma-Aldrich. Pen-Strep was purchased from Omega Scientific. The glycine-extended 
precursor of mouse joining peptide (mJP-Gly) was synthesized in-house at the USF Core 
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Peptide Synthesis and Mass Spectrometry Facility. Sep-Pak Plus C18 cartridges were 
from Waters Associates. ZipTips were from Millipore. All other reagents and solvents 
were of the highest quality commercially available. 
3.2.2 α-Amidated peptide enrichment. 
3.2.2.1 Preparation of apo-PHM by copper depletion. 
PHM (0.46 mg) was incubated with 200 µL of 100 mM MES, pH 6.0, 30 mM NaCl, 
1% (v/v) ethanol and 10 mM EDTA at 37 ºC for 1 hour. The solution was then 
transferred to 10 kDa molecular weight cut-off filter (microcon YM-10, Millipore, 
Bedford, MA, USA) and spun down at 14,000 g to 50 µL.  
3.2.2.2 Incubation with peptide mixture. 
A 150 µL aliquot of 100 mM MES, pH 6.0, 30 mM NaCl, 1% (v/v) ethanol and 10 
mM EDTA was added to the retentate together with 30 µL of substrate solution, 15 µL of 
100 mM ascorbate, 3 µL of 5.75 mg/mL catalase and 2 µL water to make the final 
volume 250 µL. The mixture was incubated at 37 ºC for 1 hour. 
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3.2.2.3 Wash. 
The volume of the mixture was reduced to 20 µL by ultrafiltration followed by the 
addition of 180 µL of 100 mM MES, pH 6.0, 30 mM NaCl, 1% (v/v) ethanol. The 
volume was again reduced to 20 µL by ultrafiltration. For enrichment experiments using 
the AtT-20 peptide extract, the wash procedure was repeated once. 
3.2.2.4 PHM reaction. 
PHM reaction buffer (80 µL) containing 100 mM MES, pH 6.0, 30 mM NaCl, 1% 
(v/v) ethanol, 25 µM CuSO4, 100 µg/mL catalase and 10 mM ascorbate was added to 20 
µL retentate. After 1 hour incubation at 37 ºC, the mixture was filtered using 10 kDa 
molecular weight cut-off filter. The pH of the filtrate was adjusted to pH 10 using 2 M 
KOH solution to convert the α-hydroxyglycine intermediate to the α-amidated product.  
3.2.3 Quantitative analysis methods. 
3.2.3.1 HPLC-fluorometric assay. 
Two dansylated peptides were used for the enrichment experiments: dansyl- 
Tyr-Val-Gly (dansyl-YVG) and dansyl-Ala-Arg (dansyl-AR). Peptide mixtures were 
analyzed with reverse-phase HPLC with a C18 column (Hypersil ODS, 4.6 × 100 mm, 5 
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µm, Keystone Scientific, Inc., Bellefonte, PA) equipped with an in-line fluorometer 
(Gilson 121, Gilson Instruments, Randolph, MA). The 8-minute gradient was 
programmed as: 30% B for 3 minutes, 30-40% B in 1 minute and 40% B for 4 minutes, 
with solvent A being 100 mM sodium acetate and solvent B being 0.1% TFA in ACN. 
The flow rate was 1.2 mL/min. The column was equilibrated with 30% B for 5 minutes 
between runs. The fluorometer was equipped with an excitation filter of 352-360 nm and 
an emission cut-off filter of 482 nm. The chromatograph peak area was calculated using a 
Hewlett-Packard integrator (HP-3392A, Hewlett-Packard, Wilmington, DE, USA). 
3.2.3.2 Relative Quantification by MALDI-TOF/TOF. 
Peptide solutions were mixed with α-cyano-4-hydroxycinnamic acid (4 mg/mL in 
50% (v/v) ACN and 5% (v/v) isopropanol) and spotted onto a blank stainless MALDI 
plate. MALDI-TOF MS was performed on an Applied Biosystems (ABI) 4700 
Proteomics Analyzer (Foster City, CA, USA) using the reflective positive mode. The data 
was externally calibrated with a standard peptide mix provided by the manufacturer. The 
peptides were quantified by their peak areas obtained from MS spectra using Data 
Explorer (Applied Biosystems, Foster City, CA, USA). The ratios of the peak areas for 
α-amidated peptides and the reference peptides were calculated manually. 
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3.2.3.3 Relative Quantification by LC-MS/MS (Extracted Ion Chromatograms).  
The sample was separated online by reversed-phase nanoflow liquid chromatograph 
(U3000, Dionex, Sunnyvale, CA, USA) with mobile phase A being  2% ACN + 0.1% 
formic acid and solvent B being 90% ACN + 0.1% formic acid. The sample was first 
loaded onto a trap column (5mm × 300 µm ID packed with C18 reversed-phase resin, 5 
µm, 100Å), washed for 8 minutes with aqueous 2% ACN and 0.04% TFA, and then 
separated with a flow rate of 300 nL/min on an analytical column (C18, 150 mm × 75 µm 
ID, Pepmap 100, Dionex, Sunnyvale, CA, USA) with a 120-minute gradient programmed 
as: 5% B for 8 minutes, 5-50% B in 90 minutes, 50-90% in 7 minutes, 90% B for 5 
minutes, 90-5% in 1 minute and 5% B for 10 minutes to re-equilibrate. Eluted peptides 
were electrosprayed directly into a hybrid Linear Ion Trap-Orbitrap mass spectrometer 
(Thermo, San Jose, CA, USA) operating in data dependent mode. Survey scan MS 
spectra were acquired in the Orbitrap with a resolution of 60,000 at m/z 400. Following 
each survey scan, the five most intense ions were selected for CID fragmentation and 
detection in the linear ion trap with 60 second exclusion. Mass measurement accuracy 
was monitored between runs using digested BSA. 
Relative quantification was done by comparing peak areas of extracted ion 
chromatograms (XICs) of the amidated peptides and the reference peptides. XICs were 
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generated from the MS spectra collected over time using the Qual Browser Software 
(Xcalibur, Thermo, San Jose, CA, USA). The peptide ratios of the α-amidated peptides 
and the reference peptides were calculated manually from the peak area of the extracted 
ions. 
3.2.4 Cell culture and sample preparation. 
 3.2.4.1 Cell growth conditions. 
Mouse pituitary AtT-20 cells were cultured in Hams F-12K culture medium 
supplemented with 15% (v/v) horse serum, 2.5% (v/v) fetal bovine serum. The cells were 
passed at a 1:3 ratio after 80% confluence. Cells were cultured in a 37ºC incubator with a 
constant flow of 5% CO2. After sufficient growth, cells were collected by centrifugation 
and evenly split into two 225 cm2 culture dishes containing 75 mL fresh media. A 75 µL 
aliquot of 5.0 mM disulfiram stock solution (prepared in 70% (v/v) ethanol) was added to 
one dish to get final disulfiram concentration of 5 µM. A 75 µL aliquot of vehicle (70% 
(v/v) ethanol) was added to the other dish as control group. The cells were incubated for 
20 hours prior to harvest. 
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3.2.4.2 Sample preparation. 
Cells were collected by centrifugation.  Cell pellet was homogenized in a ground 
glass homogenizer at 4 ºC with 8 M urea solution. The homogenate was centrifuged at 
12000g for 15 minutes. The supernatant was collected and passed through a 10 kDa 
molecular weight cut-off filter to remove proteins.  
The peptide extract was desalted and concentrated by solid phase extraction on a 
Sep-Pak Plus C18 cartridge. A Sep-Pak Plus cartridge was pre-wetted with 10 mL of 0.1% 
(v/v) TFA/80% (v/v) ACN at a flow rate of 2.0 mL/min. The cartridge was then washed 
with 20 mL aqueous solution of 0.1% (v/v) TFA/2% (v/v) ACN at a flow rate of 2.0 
mL/min. The peptide extract was loaded onto the cartridge at a rate of 1.0 mL/min, 
followed by a wash of 20 mL of 0.1% TFA (v/v) /2% (v/v) ACN at a flow rate of 1.0 
mL/min. Bound peptides were eluted with 4 mL of 0.1% (v/v) TFA/80% ACN at a flow 
rate of 1 mL/min. The 4 mL eluent was collected and concentrated to 0.5 mL using a 
Savant Speedvac vacuum centrifuge. The peptide extract from disulfiram treated group 
was then subjected to α-amidated peptide enrichment experiments. 
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3.3 Results and discussion. 
3.3.1 Enrichment experiments on dansylated short peptides. 
3.3.1.1 Separation and standardization of three model peptides. 
HPLC-fluorometric assay (Jones et al. 1988) was used to study α-amidated peptide 
enrichment with two dansylated model peptides: dansyl-Tyr-Val-Gly (dansyl-YVG) and 
dansyl-Ala-Arg (dansyl-AR). Peptide mixture was analyzed on reverse-phase HPLC 
equipped with a C18 column and a fluorometer. Under the conditions described in 
methods section, dansyl-YVG, dansyl-AR and dansyl-YV-NH2 were separated with good 
resolution. The retention times of the three peptides are listed in Table 16. 
Table 16.  Retention times of three dansylated peptides. 
  
 
Standard curves of dansyl-YVG and dansyl-AR (shown in Figure 23 and Figure 24) 
were established by injection of standard solutions to the HPLC system. 
  
Component Retention time 
Dansyl-AR 1.461 min 
Dansyl-YVG 2.326 min 
Dansyl-YV-NH2 6.400 min 
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Figure 23.  Standard curve for the detection of dansyl-YVG. 
 
Figure 24.  Standard curve for the detection of dansyl-AR. 
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3.3.1.2 Enrichment experiments. 
Dansyl-YVG (6.71 nmol) and dansyl-AR (23.71 nmol) were incubated with 0.46 mg 
apo-PHM as described in methods section. After incubation, 1.04 nmol dansyl-YVG and 
18.65 nmol dansyl-AR were found in the filtrate. The relative amount of dansyl-YVG 
significantly decreased (from 0.28:1 to 0.053:1) which indicated the specific binding to 
PHM. After washing, loaded apo-PHM was reactivated with copper. Bound dansyl-YVG 
was converted to dansyl-YV-NH2 and released from PHM. Dansyl-YV-NH2 (4.31 nmol) 
and 0.32 nmol dansyl-AR (0.32 nmol) were detected in the eluent solution. Relative 
amount of dansyl-YV-NH2 was dramatically increased to 13.46:1. Compared to the initial 
ratio 0.28:1 between dansyl-YVG and dansyl-AR, the target peptide was enriched by 
48-fold (Figure 25).  
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Figure 25.  α-Amidated peptide enrichment experiments on dansyl-YV-NH2. 
Two dansylated model peptides dansyl-Tyr-Val-Gly (d-YV-G) and dansyl-Ala-Arg 
(d-AR) were used as model peptides. Peptides were separated and detected using 
HPLC-fluorometric method as described in methods section. In the enriched sample, the 
ratio of d-YV-NH2 to d-AR increased to 13.46:1. Compared to the initial ratio( 0.28:1) of 
d-YVG and d-AR, target peptide was enriched by 48 folds.  
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3.3.2 Enrichment experiments on synthetic mJP. 
mJP-Gly was also used as a model peptide in enrichment experiments together with 
two reference peptides Ac-RFMWMK-NH2 and ELPLQNFWLCFR-NH2. A solution 
containing 100 nmol Ac-RFMWMK-NH2, 54 nmol ELPLQNFWLCFR-NH2 and 7.6 
nmol mJP-Gly was used as starting material for the enrichment experiments in which 
0.46 mg (determined by Bradford assay) apo-PHM was used. mJP-Gly was converted to 
mJP during the enrichment experiments. The peak areas of the peptides before and after 
enrichment experiments obtained by MALDI-TOF mass spectrometry (Table 17). The 
relative amount of mJP to reference peptide Ac-RFMWMK-NH2 was increased from 
0.0076:1 to 0.932:1 with 123-fold enrichment. Using ELPLQNFWLCFR-NH2 as 
reference peptide, the enrichment was 38-fold (from 0.0246:1 to 0.934:1). MS spectra are 
shown in Figure 27. 
Table 17.  Peak areas of peptides before and after enrichment experiments. 
Peptide Obs. MW 
Peak area 
Load Enriched 
Ac-RFMWMK-NH2  939.2 131103.2 97697.8 
ELPLQNFWLCFR-NH2 1494.4 40440.6 97432.2 
AEEEAVWGDGSPEPSPREG 1998.3 994.8 3390.8 
AEEEAVWGDGSPEPSPRE-NH2 1940.3 0 91051.5 
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Figure 26.  MS spectra of a peptide mixture before and after enrichment 
experiments. 
A: MS spectra of the starting peptide mixture solution containing 100 nmol 
Ac-RFMWMK-NH2 (Rf1), 54 nmol ELPLQNFWLCFR-NH2 (Rf2) and 7.6 nmol 
mJP-Gly. B: MS spectra of the peptide solution after α-amidated peptide enrichment 
experiments as described in methods section. The relative intensity of mJP was 
dramatically increased as compared to that of mJP-Gly in A. Peptides from PHM 
degradation were also detected. 
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3.3.3 Enrichment experiments on AtT-20 cell extract. 
Total peptide was extracted from both the PAM inhibitor treated group and the 
control group of AtT-20 cells with 8 M urea solution. Peptide extract from PAM 
inhibited group was subjected to α-amidated peptide enrichment experiments as 
described in methods section. All three samples were analyzed by LC-ESI-LTQ-Orbitrap 
to investigate the enrichment of one known α-amidated peptide, mJP. Shown in Table 18 
are XIC peak areas of mJP, mJP-Gly, and the four reference peptides. In the control 
sample, the intensity of one abundant reference peptide YGGFMTSEKSQTPLVTLF was 
36-fold higher than that of mJP as measured by XIC peak area. In the enriched sample, 
intensity of the reference peptide significantly dropped. The relative intensity of mJP was 
40-fold higher than the reference peptide which indicated over 1000-fold enrichment 
(Figure 27). Two less abundant reference peptides SEKSQTPLVTLF and 
WSRMoxDQLAKELTAE were not detected in the enriched sample. However, it has been 
noticed that high efficiency enrichment is not always the case with different reference 
peptides. For example, using peptide EQVLESDAEKDDGPYRVEHF as reference 
peptide, enrichment of mJP was observed to be only around 4-fold. This indicated some 
unknown interactions between this peptide and PHM prevented them from being removed 
during wash runs. 
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Table 18.  XIC peak areas of mJP and reference peptides. 
Peptide 
XIC peak area 
Control PAM inhibited Enriched 
AEEEAVWGDGSPEPSPRE-NH2 (mJP) 444480 130419 1447282 
AEEEAVWGDGSPEPSPREG (mJP-Gly) 961812 947420 54206 
YGGFMTSEKSQTPLVTLF 16260401 22224358 35157 
SEKSQTPLVTLF 902722 1361254 nd 
WSRMDQLAKELTAE 359606 223177 nd 
EQVLESDAEKDDGPYRVEHF 554703 426516 379563 
 
M denotes oxidation. nd denotes not detected. 
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Figure 27.  XICs of mJP and YGGFMTSEKSQTPLVTLF in control (top) and 
enriched (bottom) samples. 
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3.4 Conclusion. 
An α-amidated peptide enrichment method was described in this chapter. In summary, 
this method involves two steps. First, cells grown in culture are treated with PAM 
inhibitor to yield a cellular accumulation of glycine-extended peptides. It is essential that 
glycine-extended precursors present in the sample because these are the peptides bind to 
PHM and, thus, be enriched. The mature form of α-amidated peptides are likely to bind 
to PHM with relatively low affinity and are removed together with other non-binding 
peptides during the wash steps. In the second step, copper depleted apo-PHM is used to 
specifically bind glycine-extended peptides in the sample. Without bound copper, PHM 
is catalytically deficient, but still shows high selectivity. Glycine-extended peptides bind 
to apo-PHM while all other unbound peptides are removed during the wash steps. 
Activity is restored in apo-PHM with copper and is, thus, able to convert bound 
glycine-extended peptides to hydroxylated peptides, releasing them. The hydroxylated 
intermediate can be converted to α-amidated product under basic conditions. 
In enrichment experiments on synthetic model peptides, 40 – 120-fold enrichment 
was observed using HPLC-fluorometric assay or MALDI-TOF relative quantification. 
This method has also been proven to work with complex samples like cell extracts. The 
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relative intensity of mJP in AtT-20 extract was dramatically increased after enrichment 
experiments.  
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Chapter 4 Conclusions and Future Directions 
4.1 Conclusions 
In this study, a novel LC-MS/MS based strategy was developed for the discovery of 
α-amidated peptides. This strategy includes two aspects: an α-amidated peptide 
enrichment method to increase the relative concentration of target peptides in samples 
and a peptide-pair screening method to decrease the amount of MS/MS spectra to be 
interpreted.  
An α-amidated peptide correlates its glycine-extended precursor with 58.0055 Da 
mass difference, similar reverse phase retention times, and similar MS/MS fragmentation 
patterns. The glycine-extended precursor accumulates when PAM is inhibited. By 
screening for peptide pairs which meet these conditions in LC-MS/MS raw data, the 
peptide-pair screening method is able to greatly reduce the workload of spectra 
interpretation. From 15580 MS/MS spectra in an LTQ-Orbitrap dataset, the peptide-pair 
screening method identified 33 interesting pairs by using mass difference and retention 
time difference. The great reduction (over 99%) in the amount of MS/MS spectra 
requiring interpretation enabled manual interpretation which in turn increased 
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identification rate and eliminated false positives. As a result, three α-amidated peptides 
were identified from the LTQ-Orbitrap dataset in addition to the nine reported by 
database search. The peptide-pair screening method relies on the coexistence of 
α-amidated peptides and their corresponding glycine-extended precursors which is 
insured by the use of a PAM inhibitor. 
In the newly developed α-amidated peptide enrichment method, cells grown in 
culture were first treated with a PAM inhibitor to accumulate glycine-extended peptides. 
The peptide extract was then incubated with inactive, copper-depleted apo-PHM to 
specifically bind glycine-extended peptides. After the removal of unbound peptides by 
washing, PHM activity was restored by the addition of Cu2+ solution to hydroxylate and 
release bound glycine-extended peptides. Experiments on synthetic model peptides 
showed 40 – 120-fold enrichment.  
From the model cell line AtT-20, a total of 13 α-amidated peptides were successfully 
identified as listed in Table 19. Discussions about these peptides can be found in Chapter 
2. 
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Table 19.  α-Amidated peptides identified in AtT-20 cell line. 
Sequence  Precursor 
AEDQELESLSAIEAELEKVAHQLQALRR-NH2  CgA 
AEEEAVWGDGSPEPSPRE-NH2  POMC 
EEEAVWGDGSPEPSPRE-NH2  POMC 
EEAVWGDGSPEPSPRE-NH2  POMC 
EAVWGDGSPEPSPRE-NH2  POMC 
AVWGDGSPEPSPRE-NH2  POMC 
VWGDGSPEPSPRE-NH2  POMC 
 WGDGSPEPSPRE-NH2  POMC 
GDGSPEPSPRE-NH2  POMC 
DGSPEPSPRE-NH2  POMC 
GSPEPSPRE-NH2  POMC 
SYSMEHFRWGKPE-NH2  POMC 
ELEGERPL-NH2  POMC 
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4.2 Future Directions 
4.2.1 The application of α-amidated peptide enrichment method to the 
peptide-pair screening strategy. 
The PHM based α-amidated peptide enrichment method can be used in the sample 
preparation for LC-MS/MS to increase the concentration of peptides of interest and, thus, 
increase their chances of identification using a database search.  The enrichment method 
can also be used in the peptide-pair screening method together with PAM inhibition to 
insure the coexistence of α-amidated peptides and their glycine-extended precursors.  
In the peptide-pair screening strategy presented in Chapter 2, the coexistence of two 
parties in a pair was insured by combining the total peptides extracted from cells grown 
with PAM inhibitor (containing accumulated glycine-extended peptides) and from cells 
grown without PAM inhibitor (containing α-amidated peptides with natural levels). 
Instead of the total peptides extracted from the control cells, the enriched sample can be 
used to provide increased levels of α-amidated peptides. In this way, relative intensities 
of both parties in samples are increased which would facilitate the detection of less 
abundant α-amidated peptides. 
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The other future direction to apply the enrichment method to the peptide-pair 
screening strategy is to develop elution conditions in which bound glycine-extended 
peptides can be released from PHM without hydroxylation, and to provide enriched 
glycine-extended peptides. The combination of a sample containing enriched 
glycine-extended peptides with a sample containing enriched α-amidated peptides would 
greatly reduce the sample complexity and render LC-MS/MS more efficient and effective. 
Possible elution conditions to be considered include high concentration of urea/ 
guanidine which was used to elute biotin from avidin (Diamandis and Christopoulos 1991, 
Buckie and Cook 1986), and low pH which was used to elute peptides with C-terminal 
basic residues (Lys or Arg) from anhydrotrypsin (Yokosawa and Ishii 1979, Ishii et al. 
1983, Kumazaki et al. 1986).   
4.2.2 Application of peptide-pair strategy to screen for other PTMs. 
The peptide-pair strategy can be easily adapted to screen for peptides with other 
modifications. Mass differences between modified and unmodified form for common 
PTMs are shown in Table 21. Similar retention time and similar MS/MS fragmentation 
patterns between modified and unmodified peptides can be expected for most PTMs. The 
only requirement of the peptide-pair strategy is that modified and unmodified forms of 
peptides coexist. For most reversible modifications, this condition is usually fulfilled due 
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to their dynamic nature. Proper treatment of the sample can increase the concentration of 
the less abundant party and thus make it more detectable. Taking S-glutathionylation as 
an example, if modified peptide level is low, oxidative and nitrosative stress can be 
introduced to induce S-glutathionylation (Klatt and Lamas 2000); if unmodified peptide 
level is low, glutaredoxin can be used for deglutathionylation (Mieyal et al. 2008). 
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Table1 20.  Mass changes due to some PTMs. 
Modification Site Monoisotopic 
mass change 
Acetylation Lys/N-terminus 42.0373 
Biotinylation Lys/N-terminus 226.2994 
Carboxylation  Glu/Asp 44.0098 
Cysteinylation Cys 119.1442 
Deamidation  Gln/Asn 0.9847 
Deoxyhexoses Ser/Thr/Asn 146.143 
Disulphide bond Cys -2.0159 
Farnesylation Lys/N-terminus 204.3556 
Formylation Lys/N-terminus 28.0104 
Geranylgeranylation Lys/N-terminus 272.4741 
Glutathionylation Cys 305.3117 
Hexosamines Ser/Thr/Asn 161.1577 
Hexoses Ser/Thr/Asn 162.1424 
Lipoic acid Lys/N-terminus 188.3147 
Methylation Lys/N-terminus 14.0269 
Myristoylation Lys/N-terminus 210.3598 
N-acetylhexosamines Ser/Thr/Asn 203.195 
Oxidation Cys 15.9994 
Palmitoylation Lys/N-terminus 238.4136 
Pentoses Ser/Thr/Asn 132.1161 
Phosphorylation Ser/Thr/Tyr 79.9799 
Pyroglutamic acid  Gln -17.0306 
Sialic acid Ser/Thr/Asn 291.2579 
Stearoylation Lys/N-terminus 266.4674 
Sulphation Ser/Thr/Tyr 80.0642 
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Appendix A: Abbreviations 
ACE Angiotensin-Converting Enzyme  
ACN Acetonitrile 
CCK  Cholecystokinin 
CCK-AR Cholecystokinin-A receptor  
CgA Chromogranin A 
CHCA α-Cyano-4-hydroxycinnamic acid 
CID Collision-induced dissociation  
CRH Corticotropin-releasing hormone  
Dansyl  5-Dimethylamino-naphthalene-1-sulfonyl chloride 
DMAB 3-(Dimethylamino)benzoic acid 
ECD Electron capture dissociation  
EDTA Ethylenediaminetetraacetic acid 
ESI Electrospray ionization 
FAB Fast atom bombardment  
HHL Hippuryl-L-histidyl-L-leucine  
HPLC High performance liquid chromatography 
HRP Horse Radish Peroxidase 
JP Joining peptide  
LC Liquid chromatography  
LC-MS/MS Liquid chromatography coupled tandem mass spectrometry  
LOD Limit of detection 
LPH Lipotropin  
LTQ Linear ion trap 
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Luminol  3-Aminophthalhydrazide 
MALDI Matrix assisted laser desorption ionization 
MBTH  3-Methyl-2-benzothiazolinone hydrazone 
MDF Mass Distance Fingerprint  
MDH Mass Distance Histogram  
MES 2-(N-Morpholino)ethanesulfonic acid 
mJP Mouse joining peptide  
MS Mass spectrometry  
MS/MS Tandem mass spectrometry  
MSH  Melanotropin  
MWCO  Molecular weight cut-off 
NAD+/NADH  Nicotinomide adenine dinucleotide/nicotinamide adenine dinucleotide 
reduced form 
NADP+/NADP
H  
Nicotinamide adenine dinucleotide phosphate/Nicotinamide adenine 
dinucleotide phosphate reduced form 
NERP Neuroendocrine regulatory peptide 
NPY Neuropeptide Y 
PAL Peptidylamidoglycolate lyase 
PAM Peptidylglycine a-amidating monooxygenase  
PHM Peptidylglycine a-hydroxylating monooxygenase  
PMS Phenazine methosulfonate  
POMC Pro-opiomelanocortin  
PTM Post-translational modification  
RT Retention time 
S/N  Sinal over noise 
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TFA Trifluoroacetic acid 
TLC  Thin layer chromatography 
TOF Time of flight 
TRH Thyrotropin releasing hormone  
XIC Extracted ion chromatogram 
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Appendix B: Figures  
 
Figure 28.  Standard curve for the quantification of hippuric acid. 
 
Figure 29.  Standard curve for the quantification of phosphorus.
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Figure 30.  Identification of α-amidated peptide AEEEAVWGDGSPEPSPRE-NH2. 
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Figure 31.  Identification of α-amidated peptide EEEAVWGDGSPEPSPRE-NH2. 
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Figure 32.  Identification of α-amidated peptide EEAVWGDGSPEPSPRE-NH2. 
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Figure 33.  Identification of α-amidated peptide EAVWGDGSPEPSPRE-NH2. 
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Figure 34.  Identification of α-amidated peptide AVWGDGSPEPSPRE-NH2. 
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Figure 35.  Identification of α-amidated peptide VWGDGSPEPSPRE-NH2. 
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Figure 36.  Identification of α-amidated peptide WGDGSPEPSPRE-NH2. 
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Figure 37.  Identification of α-amidated peptide GDGSPEPSPRE-NH2. 
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Figure 38.  Identification of α-amidated peptide DGSPEPSPRE-NH2. 
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Figure 39.  Identification of α-amidated peptide GSPEPSPRE-NH2. 
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Figure 40.  Identification of α-amidated peptide SYSMEHFRWGKPV-NH2. 
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Figure 41.  Identification of peptidePEPSRSTPAPKKGSKK.
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Figure 42.  Identification of peptide PEPSKSAPAPKKGSKK. 
Top: MS/MS spectrum; Bottom: MS/MS/MS spectrum of y12+2 ion. 
